Hematoimmuno 1
==NILAI PRETEST Pre-postest Hematoimmuno 1
11 • B lymphocytes • B regulatory cells • CD classification of human lymphocyte differentiation antigens cluster of differentiation • CD4 T cell • CD8 T cell • Chemokines • Complement • Co-stimulatory molecules • Crystallopathies • Cytokines • Dendritic cells • Ig Fc receptors γ ε γ γ α • Inflammasome β • Innate immune system • Large granular lymphocytes Section 1 The Immune System in Health and Disease ■DEFINITIONS • Adaptive immune system • Antibody • Antigens • Antimicrobial peptides • Apoptosis programmed cell death cell necrosis • Autoimmune diseases • Autoinflammatory diseases • Autophagy • B cell receptor for antigen αβ 342Introduction to the Immune System Barton F. Haynes, Kelly A. Soderberg, Anthony S. Fauci PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2452 • Natural killer cells • NK T cells α β • Pathogen-associated molecular patterns • Pattern recognition receptors • Polyreactive natural antibodies— • T lymphocytes • T cell exhaustion— • T cell receptor (TCR) for antigen α β γ δ ε ζ η α β • T follicular helper T cells (Tfh) • Th 1 T cells • Th 2 T cells • T regulatory cell (Treg) • T9 T cells • T17 T cells γ • Tolerance ■INTRODUCTION innate immune system adaptive immune system specificity immune memory (Table 342-1) ■THE INNATE IMMUNE SYSTEM (Tables 342-2 and 342-3) ■PATTERN RECOGNITION collectins CHAPTER 342 Introduction to the Immune System 2453 (Continued) TABLE 342-1 Human Leukocyte Surface Antigens—The CD Classification of Leukocyte Differentiation Antigens (Continued) SURFACE ANTIGEN (OTHER NAMES) FAMILY MOLECULAR MASS, kDa DISTRIBUTION LIGAND(s) FUNCTION CD1a (T6, HTA-1) Ig 49 CD, cortical thymocytes, Langerhans type of DCs TCRγδ T cells CD1 molecules present lipid antigens of intracellular bacteria such as Mycobacterium leprae and M. tuberculosis to TCRγδT cells CD1b Ig 45 CD, cortical thymocytes, Langerhans type of DCs TCRγδ T cells CD1c Ig 43 DC, cortical thymocytes, subset of B cells, Langerhans type of DCs TCRγδ T cells CD1d Ig 37 Cortical thymocytes, intestinal epithelium, Langerhans type of DCs TCRγδ T cells CD2 (T12, LFA-2) Ig 50 T, NK CD58, CD48, CD59, CD15 Alternative T cell activation, T cell anergy, T cell cytokine production, T- or NK-mediated cytolysis, T cell apoptosis, cell adhesion CD3 (T3, Leu-4) Ig γ:25–28, δ:21–28, ε:20–25, η:21–22, ζ:16 T Associates with the TCR T cell activation and function; ζ is the signal transduction component of the CD3 complex CD4 (T4, Leu-3) Ig 55 T, myeloid MHC-II, HIV, gp120, IL-16, SABP T cell selection, T cell activation, signal transduction with p56lck, primary receptor for HIV CD7 (3A1, Leu-9) Ig 40 T, NK K-12 (CD7L) T and NK cell signal transduction and regulation of IFN-γ, TNF-α production CD8 (T8, Leu-2) Ig 34 T MHC-I T cell selection, T cell activation, signal transduction with p56lck CD14 (LPS-receptor) LRG 53–55 M, G (weak), not by myeloid progenitors Endotoxin (lipopolysaccharide), lipoteichoic acid, PI TLR4 mediates with LPS and other PAMP activation of innate immunity CD16a (FcγRIIIa) Ig 50–80 NK, macrophages, neutrophils Fc portion of IgG Mediates phagocytosis and ADCC CD19 B4 Ig 95 B (except plasma cells), FDC Not known Associates with CD21 and CD81 to form a complex involved in signal transduction in B cell development, activation, and differentiation CD20 (B1) Unassigned 33–37 B (except plasma cells) Not known Cell signaling, may be important for B cell activation and proliferation CD21 (B2, CR2, EBV-R, C3dR) RCA 145 Mature B, FDC, subset of thymocytes C3d, C3dg, iC3b, CD23, EBV Associates with CD19 and CD81 to form a complex involved in signal transduction in B cell development, activation, and differentiation; Epstein-Barr virus receptor CD22 (BL-CAM) Ig 130–140 Mature B CDw75 Cell adhesion, signaling through association with p72sky, p53/56lyn, PI3 kinase, SHP1, fLCγ CD23 (FcεRII, B6, Leu-20, BLAST-2) C-type lectin 45 B, M, FDC IgE, CD21, CD11b, CD11c Regulates IgE synthesis, cytokine release by monocytes CD28 Ig 44 T, plasma cells CD80, CD86 Co-stimulatory for T cell activation; involved in the decision between T cell activation and anergy CD32a (FcγRIIa) Ig 40 NK, macrophages, neutrophils Fc portion of IgG Mediates phagocytosis and ADCC CD40 TNFR 48–50 B, DC, EC, thymic epithelium, MP, cancers CD154 B cell activation, proliferation, and differentiation; formation of GCs; isotype switching; rescue from apoptosis CD45 (LCA, T200, B220) PTP 180, 200, 210, 220 All leukocytes Galectin-1, CD2, CD3, CD4 T and B activation, thymocyte development, signal transduction, apoptosis CD45RA PTP 210, 220 Subset T, medullary thymocytes, “naive” T Galectin-1, CD2, CD3, CD4 Isoforms of CD45 containing exon 4 (A), restricted to a subset of T cells CD45RB PTP 200, 210, 220 All leukocytes Galectin-1, CD2, CD3, CD4 Isoforms of CD45 containing exon 5 (B) CD45RC PTP 210, 220 Subset T, medullary thymocytes, “naive” T Galectin-1, CD2, CD3, CD4 Isoforms of CD45 containing exon 6 (C), restricted to a subset of T cells CD45RO PTP 180 Subset T, cortical thymocytes, “memory” T Galectin-1, CD2, CD3, CD4 Isoforms of CD45 containing no differentially spliced exons, restricted to a subset of T cells PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2454 Toll-like receptor proteins Fig. 342-1 (Tables 342-4 and 342-5) TABLE 342-1 Human Leukocyte Surface Antigens—The CD Classification of Leukocyte Differentiation Antigens (Continued) CD64 (FcγRI) Ig 45–55 Macrophages and monocytes Fc portion of IgG Mediates phagocytosis and ADCC CD80 (B7-1, BB1) Ig 60 Activated B and T, MP, DC CD28, CD152 Co-regulator of T cell activation; signaling through CD28 stimulates and through CD152 inhibits T cell activation CD86 (B7-2, B70) Ig 80 Subset B, DC, EC, activated T, thymic epithelium CD28, CD152 Co-regulator of T cell activation; signaling through CD28 stimulates and through CD152 inhibits T cell activation CD89 (FCαR) Ig 55–100 Neutrophils, eosinophils, monocytes, and MP Fc portion of IgG Mediates phagocytosis and ADCC of IgA-coated pathogens CD95 (APO-1, Fas) TNFR 43 Activated T and B Fas ligand Mediates apoptosis CD152 (CTLA-4) Ig 30–33 Activated T CD80, CD86 Inhibits T cell proliferation CD154 (CD40L) TNF 33 Activated CD4+ T, subset CD8+ T, NK, M, basophil CD40 Co-stimulatory for T cell activation, B cell proliferation and differentiation CD279 (PD-1) Ig 50–55 B, T, TfH PD-L1, PD-L2 Inhibits T cell proliferation Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CTLA, cytotoxic T lymphocyte–associated protein; DC, dendritic cells; EBV, Epstein-Barr virus; EC, endothelial cells; ECM, extracellular matrix; Fcγ RIII, low-affinity IgG receptor isoform A; FDC, follicular dendritic cells; G, granulocytes; GC, germinal center; GPI, glycosyl phosphatidylinositol; HTA, human thymocyte antigen; Ig, immunoglobulin; IgG, immunoglobulin G; LCA, leukocyte common antigen; LPS, lipopolysaccharide; MHC-I, major histocompatibility complex class I; MP, macrophages; Mr, relative molecular mass; NK, natural killer cells; P, platelets; PBT, peripheral blood T cells; PD-1, programmed cell death-1; PI, phosphatidylinositol; PI3K, phosphatidylinositol 3-kinase; PLC, phospholipase C; PTP, protein tyrosine phosphatase; TCR, T cell receptor; TfH, T follicular helper cells; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor. For an expanded list of cluster of differentiation (CD) human antigens, see Harrison’s Online at http://www.accessmedicine.com; and for a full list of CD human antigens from the most recent Human Workshop on Leukocyte Differentiation Antigens (VII), see http://mpr.nci.nih.gov/prow/. Source: Compiled from T Kishimoto et al (eds): Leukocyte Typing VI. New York: Garland Publishing, 1997; R Brines et al: Immunology Today 18S:1, 1997; and S Shaw (ed): Protein reviews on the Web. http://mpr.nci.nih.gov/prow/. TABLE 342-2 Major Components of the Innate Immune System Pattern recognition receptors (PRRs) Toll-like receptors (TLRs), C-type lectin receptors (CLRs), retinoic acid–inducible gene (RIG)-1-like receptors (RLRs), and NOD-like receptors (NLRs) Antimicrobial peptides α-Defensins, β-defensins, cathelin, protegrin, granulysin, histatin, secretory leukoprotease inhibitor, and probiotics Cells Macrophages, dendritic cells, NK cells, NK-T cells, neutrophils, eosinophils, mast cells, basophils, and epithelial cells Complement components Classic and alternative complement pathway, and proteins that bind complement components Cytokines Autocrine, paracrine, endocrine cytokines that mediate host defense and inflammation, as well as recruit, direct, and regulate adaptive immune responses Abbreviation: NK, natural killer. inflammasomes β autoinflammatory syndromes (Table 342-6) ■EFFECTOR CELLS OF INNATE IMMUNITY Monocytes-Macrophages (Fig. 342-2) CHAPTER 342 Introduction to the Immune System 2455 TABLE 342-3 Pattern Recognition Receptors (PRRs) and Their Ligands PRRs LOCALIZATION LIGAND ORIGIN OF THE LIGAND TLR TLR1 Plasma membrane Triacyl lipoprotein Bacteria TLR2 Plasma membrane Lipoprotein Bacteria, viruses, parasite, self TLR3 Endolysosome dsRNA Virus TLR4 Plasma membrane LPS Bacteria, viruses, self TLR5 Plasma membrane Flagellin Bacteria TLR6 Plasma membrane Diacyl lipoprotein Bacteria, viruses TLR7 (human TLR8) Endolysosome ssRNA Virus, bacteria, self TLR9 Endolysosome CpG-DNA Virus, bacteria, protozoa, self TLR10 Endolysosome Unknown Unknown TLR11 Plasma membrane Profilin-like molecule Protozoa RLR RIG-I Cytoplasm Short dsRNA, triphosphate dsRNA RNA viruses, DNA virus MDA5 Cytoplasm Long dsRNA RNA viruses (Picornaviridae) LGP2 Cytoplasm Unknown RNA viruses NLR NOD1 Cytoplasm iE-DAP Bacteria NOD2 Cytoplasm MDP Bacteria CLR Dectin-1 Plasma membrane β2-Glucan Fungi Dectin-2 Plasma membrane β2-Glucan Fungi MINCLE Plasma membrane SAP130 Self, fungi Abbreviations: CLR, C-type lectin receptors; dsRNA, double-strand RNA; iE-DAP, D-glutamyl-meso-diaminopimelic acid moiety; LGP2, Laboratory of Genetics and Physiology 2 protein encoded by the gene DHX58; MDA5, melanoma differentiation-associated protein 5; MDP, MurNAc-L-Ala-D-isoGln, also known as muramyl dipeptide; MINCLE, macrophage-inducible C-type lectin; NLR, NOD-like receptor; NOD, NOTCH protein domain; RIG, retinoic acid–inducible gene; RLR, RIG-like receptors; TLR, Toll-like receptor. Source: Adapted from O Takeuchi, S Akira: Cell 140:805, 2010, with permission. CD14 LPS Inflammatory cytokines and/ or chemokines Nucleus TLR9 CpG ssRNA Endosome TLR7 or TLR8 MYD88 MYD88 MYD88 TIRAP TRIF TRIF TRAM Triacylated lipopeptides Diacylated lipopeptides Flagellin Unknown TLR4 TLR2 TLR1 TLR2 TLR6 TLR5 TLR10 Flagellin TLR 11 Plasma membrane TRAF-6 IRAK NF-κB MAPK NF-κB IFN-β IRF3 IRF3 TLR3 dsRNA Endosome FIGURE 342-1 Overview of major TLR signaling pathways. All TLRs signal through MYD88, with the exception of TLR3. TLR4 and the TLR2 subfamily (TLR1, TLR2, TLR6) also engage TIRAP (Toll-interleukin 1 receptor domain-containing adapter protein). TLR3 signals through TRIF (Toll-interleukin 1 receptor domain-containing adapter inducing interferon-β). TRIF is also used in conjunction with TRAM (TRIF-related adaptor molecule) in the TLR4-MYD88-independent pathway. Dashed arrows indicate translocation into the nucleus. dsRNA, double-strand RNA; IFN, interferon; IRF3, interferon regulatory factor 3; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinases; NF-κB, nuclear factor-κB; ssRNA, single-strand RNA; TLR, Toll-like receptor. (Adapted from D van Duin et al: Trends Immunol 27:49, 2006, with permission.) PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2456 leukotrienes; platelet activating factor; cytokines such as IL-1, TNF-α, IL-6, and IL-12; and chemokines (Tables 342-7 to 342-9). Although monocytes-macrophages were originally thought to be the major APCs of the immune system, it is now clear that cell types called dendritic cells are the most potent and effective APCs in the body (see below). Monocytes-macrophages mediate innate immune effector functions such as destruction of antibody-coated bacteria, tumor cells, or even normal hematopoietic cells in certain types of autoimmune cytopenias. Monocytes-macrophages ingest bacteria or are infected by viruses, and in doing so, they frequently undergo programmed cell death or apoptosis. Macrophages that are infected by intracellular infec tious agents are recognized by DCs as infected and apoptotic cells and are phagocytosed by DCs. In this manner, DCs “cross-present” infec tious agent antigens of macrophages to T cells. Activated macrophages can also mediate antigen-nonspecific lytic activity and eliminate cell types such as tumor cells in the absence of antibody. This activity is largely mediated by cytokines (i.e., TNF-α and IL-1). Monocytes- macrophages express lineage-specific molecules (e.g., the cell-surface LPS receptor, CD14) as well as surface receptors for a number of mol ecules, including the Fc region of IgG, activated complement compo nents, and various cytokines (Table 342-7). Dendritic Cells Human DCs contain several subsets, including myeloid DCs and plasmacytoid DCs. Myeloid DCs can differenti ate into either macrophages-monocytes or tissue-specific DCs. In contrast to myeloid DCs, plasmacytoid DCs are inefficient APCs but are potent producers of type I IFN (e.g., IFN-α) in response to viral infections. The maturation of DCs is regulated through cell-to cell contact and soluble factors, and DCs attract immune effectors through secretion of chemokines. When DCs come in contact with bacterial products, viral proteins, or host proteins released as danger signals from distressed host cells (Fig. 342-2), infectious agent mole cules bind to various TLRs and activate DCs to release cytokines and chemokines that drive cells of the innate immune system to become activated to respond to invading organisms, and recruit T and B cells of the adaptive immune system to respond. Plasmacytoid DCs produce antiviral IFN-α that activates NK cell killing of pathogen- infected cells; IFN-α also activates T cells to mature into antipatho gen cytotoxic (killer) T cells. Following contact with pathogens, both plasmacytoid and myeloid DCs produce chemokines that attract helper and cytotoxic T cells, B cells, polymorphonuclear cells, and naïve and memory T cells as well as regulatory T cells to ultimately dampen the immune response once the pathogen is controlled. TLR engagement on DCs upregulates MHC class II, B7-1 (CD80), and B7-2 (CD86), which enhance DC-specific antigen presentation and induce cytokine production (Table 342-7). Thus, DCs are important bridges between early (innate) and later (adaptive) immunity. DCs also modulate and determine the types of immune responses induced by pathogens via the TLRs expressed on DCs (TLR7–9 on plasmacytoid DCs, TLR4 on monocytoid DCs) and via the TLR adapter proteins that are induced to associate with TLRs (Fig. 342-1, Table 342-4). In addition, other PRRs, such as C-type lectins, NLRs, and mannose receptors, upon ligation by pathogen products, activate cells of the adaptive immune system and, like TLR stimulation, by a variety of factors, determine the type and quality of the adaptive immune response that is triggered (Table 342-4). Large Granular Lymphocytes/Natural Killer Cells LGLs or NK cells account for ~5–15% of peripheral blood lymphocytes. NK cells are nonadherent, nonphagocytic cells with large azurophilic TABLE 342-4 The Role of Pattern Recognition Receptors (PRRs) in Modulation of Adaptive Immune Responses PRR FAMILY PRRS LIGAND DC OR MACROPHAGE CYTOKINE RESPONSE ADAPTIVE IMMUNE RESPONSE TLRs TLR2 (heterodimer with TLR1 or 6) Lipopeptides Pam-3-cys (TLR 2/1) Low IL-12p70 High IL-10 TH 1 TH 2 MALP (TLR 2/6) IL-6 T regulatory TLR3 dsRNA IL-12p70 TH 1 IFN-α IL-6 TLR4 Escherichia coli LPS High IL-12p70 TH 1 Intermediate IL-10 IL-6 TLR5 Flagellin High IL-12p70 TH 1 Low IL-12p70 TH 2 TLR7/8 ssRNA High IL-12p70 TH 1 Imidazoquinolines IFN-α IL-6 TLR9 CpG DNA High IL-12p70 TH 1 Low IL-10 IL-6 IFN-α TLR10 ? ? ? TLR11 Profilin-like molecule uropathogenic bacteria ? ? C-type lectins DC-SIGN Env of HIV; core protein of HCV; components of Mycobacterium tuberculosis; Helicobacter pylori, Lewis Ag H. pylori, Lewis Ag Suppresses IL-12p70 Suppresses TLR signaling in DCs TH 2 T regulatory NOD NOD2 Muramyl dipeptide of peptidoglycan of bacteria Induces IL-10 in DCs Weak T cell response (tolerogenic?) Mannose receptor Mannose receptor Mannosylated lipoarabinomannans from bacillus Calmette-Guérin and M. tuberculosis Suppresses IL-12 and TLR signaling in DCs Weak T cell response? (tolerogenic?) Abbreviations: CpG, sequences in DNA recognized by TLR-9; DC, dendritic cell; DC-SIGN, DC-specific C-type lectin; dsRNA, double-strand RNA; HCV, hepatitis C virus; HIV, human immunodeficiency virus; LPS, lipopolysaccharide; MALP, macrophage-activating lipopeptide; NOD, NOTCH protein domain; ssRNA, single-strand RNA; TH 1, helper T cell; TH 2, helper T cell; TLR, Toll-like receptor. Source: B Pulendran: J Immunol 174:2457, 2005. Copyright 2005 The American Association of Immunologists, Inc., with permission. CHAPTER 342 Introduction to the Immune System 2457 cytoplasmic granules. NK cells express surface receptors for the Fc portion of IgG (FcR) (CD16) and for NCAM-I (CD56), and many NK cells express T lineage markers, particularly CD8, and proliferate in response to IL-2. NK cells arise in both bone marrow and thymic microenvironments. Functionally, NK cells share features with both monocytes- macrophages and neutrophils in that they mediate both antibody- dependent cellular cytotoxicity (ADCC) and NK cell activity. ADCC is the binding of an opsonized (antibody-coated) target cell to an Fc receptor-bearing effector cell via the Fc region of antibody, resulting in lysis of the target by the effector cell. NK cell cytotoxicity is the nonimmune (i.e., effector cell never having had previous contact with the target), MHC-unrestricted, non-antibody-mediated killing of target cells, which are usually malignant cell types, transplanted foreign cells, or virus-infected cells. Thus, NK cell cytotoxicity may play an impor tant role in immune surveillance and destruction of malignant and virus-infected host cells. NK cell hyporesponsiveness is also observed in patients with Chédiak-Higashi syndrome, an autosomal recessive disease associated with fusion of cytoplasmic granules and defective degranulation of neutrophil lysosomes. NK cells have a variety of surface receptors that have inhibitory or activating functions and belong to two structural families. These families include the immunoglobulin superfamily and the lectin-like type II transmembrane proteins. NK immunoglobulin superfamily receptors include the killer cell immunoglobulin-like activating or inhibitory receptors (KIRs), many of which have been shown to have HLA class I ligands. The KIRs are made up proteins with either two (KIR2D) or three (KIR3D) extracellular immunoglobulin domains (D). Moreover, their nomenclature designates their function as either inhibitory KIRs with a long (L) cytoplasmic tail and immunoreceptor tyrosine-based inhibitory motif (ITIM) (KIRDL) or activating KIRs with a short (S) cytoplasmic tail (KIRDS). NK cell inactivation by KIRs is a central mechanism to prevent damage to normal host cells. Genetic studies have demonstrated the association of KIRs with viral infection outcome and autoimmune disease (Table 342-10). In addition to the KIRs, a second set of immunoglobulin superfamily receptors includes the natural cytotoxicity receptors (NCRs), which include NKp46, NKp30, and NKp44. These receptors help to mediate NK cell activation against target cells. The ligands to which NCRs bind on target cells have been recently recognized to be comprised of mole cules of pathogens such as influenza, cytomegalovirus, and malaria as well as host molecules expressed on tumor cells. NK cell signaling is, therefore, a highly coordinated series of inhib iting and activating signals that prevent NK cells from responding to uninfected, nonmalignant self-cells; however, they are activated to attack malignant and virally infected cells (Fig. 342-3). Recent evidence suggests that NK cells, although not possessing rearranging immune recognition genes, may be able to mediate recall for NK cell responses to viruses and for immune responses such as contact hypersensitivity. Some NK cells express CD3 and invariant TCR-α chains and are termed NK T cells. TCRs of NK T cells recognize lipid molecules of intracellular bacteria when presented in the context of CD1d molecules on APCs. Upon activation, NK T cells secrete effector cytokines such as IL-4 and IFN-γ. This mode of recognition of intracellular bacteria such TABLE 342-5 Cells of the Innate Immune System and Their Major Roles in Triggering Adaptive Immunity CELL TYPE MAJOR ROLE IN INNATE IMMUNITY MAJOR ROLE IN ADAPTIVE IMMUNITY Macrophages Phagocytose and kill bacteria; produce antimicrobial peptides; bind LPS; produce inflammatory cytokines Produce IL-1 and TNF-α to upregulate lymphocyte adhesion molecules and chemokines to attract antigen-specific lymphocyte. Produce IL-12 to recruit TH 1 T helper cell responses; upregulate co-stimulatory and MHC molecules to facilitate T and B lymphocyte recognition and activation. Macrophages and dendritic cells, after LPS signaling, upregulate co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) that are required for activation of pathogen specific T cells. There are also Toll-like proteins on B cells and dendritic cells that, after LPS ligation, induce CD80 and CD86 on these cells for T cell antigen presentation. Plasmacytoid dendritic cells (DCs) of lymphoid lineage Produce large amounts of interferon-α (IFN-α), which has antitumor and antiviral activity, and are found in T cell zones of lymphoid organs; they circulate in blood IFN-α is a potent activator of macrophage and mature DCs to phagocytose invading pathogens and present pathogen antigens to T and B cells Myeloid dendritic cells are of two types: interstitial and Langerhans-derived Interstitial DCs are strong producers of IL-12 and IL-10 and are located in T cell zones of lymphoid organs, circulate in blood, and are present in the interstices of the lung, heart, and kidney; Langerhans DCs are strong producers of IL-12; are located in T cell zones of lymph nodes, skin epithelia, and the thymic medulla; and circulate in blood Interstitial DCs are potent activators of macrophage and mature DCs to phagocytose invading pathogens and present pathogen antigens to T and B cells Natural killer (NK) cells Kill foreign and host cells that have low levels of MHC+ self-peptides. Express NK receptors that inhibit NK function in the presence of high expression of self-MHC. Produce TNF-α and IFN-γ, which recruit TH 1 helper T cell responses NK-T cells Lymphocytes with both T cell and NK surface markers that recognize lipid antigens of intracellular bacteria such as Mycobacterium tuberculosis by CD1 molecules and kill host cells infected with intracellular bacteria. Produce IL-4 to recruit TH 2 helper T cell responses, IgG1 and IgE production Neutrophils Phagocytose and kill bacteria, produce antimicrobial peptides Produce nitric oxide synthase and nitric oxide, which inhibit apoptosis in lymphocytes and can prolong adaptive immune responses Eosinophils Kill invading parasites Produce IL-5, which recruits Ig-specific antibody responses Mast cells and basophils Release TNF-α, IL-6, and IFN-γ in response to a variety of bacterial PAMPs Produce IL-4, which recruits TH 2 helper T cell responses, and recruit IgG1- and IgE-specific antibody responses Epithelial cells Produce antimicrobial peptides; tissue-specific epithelia produce mediator of local innate immunity; e.g., lung epithelial cells produce surfactant proteins (proteins within the collectin family) that bind and promote clearance of lung-invading microbes Produces TGF-β, which triggers IgA-specific antibody responses Abbreviations: IL-4, IL-5, IL-6, IL-10, and IL-12, interleukin 4, 5, 6, 10, and 12, respectively; MHC, major histocompatibility complex: LPS, lipopolysaccharide; PAMP, pathogen associated molecular patterns; TH , helper T cell; TNF-α, tumor necrosis factor-alpha. Source: Adapted from R Medzhitov, CA Janeway: Curr Opinion Immunol 9:4, 1997. Copyright 1997, with permission from Elsevier. PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2458 as Listeria monocytogenes and Mycobacterium tuberculosis by NK T cells leads to induction of activation of DCs and is thought to be an important innate defense mechanism against these organisms. The receptors for the Fc portion of IgG (FcγRs) are present on NK cells, B cells, macrophages, neutrophils, and mast cells and mediate interactions of IgG with antibody-coated target cells, such as virally infected cells. Antibody-NK interaction via antibody Fc and NK cell FcR links the adaptive and innate immune systems and regulates the mediation of IgG antibody effector functions such as ADCC. There are both activation and inhibitory FcγRs. Activation FcRs, such as FcγRI (CD64), FcγRIIa (CD32a), and FcγRIIIa (CD16a), are characterized by the presence of an immunoreceptor tyrosine-based activating motif (ITAM) sequence, whereas inhibitory FcRs, such as FcγRIIb (CD32b), contain an ITIM sequence. There is evidence that dysregulation in IgG-FcγR interactions plays roles in arthritis, multiple sclerosis, and systemic lupus erythematosus. Neutrophils, Eosinophils, and Basophils Granulocytes are present in nearly all forms of inflammation and are amplifiers and effectors of innate immune responses (Fig. 342-2). Unchecked accumu lation and activation of granulocytes can lead to host tissue damage, as seen in neutrophil- and eosinophil-mediated systemic necrotizing vasculitis. Granulocytes are derived from stem cells in bone marrow. Each type of granulocyte (neutrophil, eosinophil, or basophil) is derived from a different subclass of progenitor cell that is stimulated to proliferate by colony-stimulating factors (Table 342-7). During terminal maturation of granulocytes, class-specific nuclear morphology and cytoplasmic granules appear that allow for histologic identification of granulocyte type. Neutrophils express Fc receptor IIIa for IgG (CD16a) as well as receptors for activated complement components (C3b or CD35). Upon interaction of neutrophils with antibody-coated (opsonized) bacteria or immune complexes, azurophilic granules (containing myeloperox idase, lysozyme, elastase, and other enzymes) and specific granules (containing lactoferrin, lysozyme, collagenase, and other enzymes) are released, and microbicidal superoxide radicals (O2–) are generated at the neutrophil surface. The generation of superoxide leads to inflam mation by direct injury to tissue and by alteration of macromolecules such as collagen and DNA. Eosinophils are potent cytotoxic effector cells for various parasitic organisms. In Nippostrongylus brasiliensis helminth infection, eosino phils are important cytotoxic effector cells for removal of these par asites. Key to regulation of eosinophil cytotoxicity to N. brasiliensis worms are antigen-specific T helper cells that produce IL-4, thus providing an example of regulation of innate immune responses by adaptive immunity antigen-specific T cells. Intracytoplasmic contents of eosinophils, such as major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin, are capable of directly damaging tissues and may be responsible in part for the organ system dys function in the hypereosinophilic syndromes (Chap. 60). Because the TABLE 342-6 Diseases Associated with Inflammasome Activity DISEASE CLINICAL FEATURES GENE MUTATED ETIOLOGIC AGENT INFLAMMASOME INVOLVEMENT ANAKINRA RESPONSEa Familial cold autoinflammatory syndrome (FCAS) Fever, arthralgia, cold induced urticaria NALP3 Overactive Yes Muckle-Wells syndrome (MWS) Fever, arthralgia, urticaria, sensorineural deafness, amyloidosis NLRP3 Overactive Yes Chronic infantile neurologic cutaneous and articular syndrome (CINCA, NOMID) Fever, severe arthralgia, urticaria, neurologic problems, severe amyloidosis NALP3 Overactive Yes Familial Mediterranean fever (FMF) Fever, peritonitis, pleuritis, amyloidosis Pyrin Overactive Partial Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA) Pyogenic sterile arthritis PSTPIP1 Overactive Yes Hyperimmunoglobulin D syndrome (HIDS) Arthralgia, abdominal pain, lymphadenopathy Mevalonate kinase To be demonstrated Yes Tumor necrosis factor receptor-1–associated syndrome (TRAPS) Fever, abdominal pain, skin lesions TNF-R1 To be demonstrated Yes Systemic-onset juvenile idiopathic arthritis (SOJIA) Chronic joint inflammation Unknown To be demonstrated Yes Adult-onset Still’s disease (AOSD) Arthralgia, fever Unknown To be demonstrated Yes Behçet’s disease Arthralgia, uveitis, ulcers Unknown To be demonstrated Yes Schnitzler’s syndrome Urticaria, fever, arthralgia Unknown To be demonstrated Yes Gout Metabolic arthritis, pain Uric acid (MSU) Activated Yes Pseudogout Arthritis CPPD Activated Yes Contact dermatitis Urticaria Irritants Activated Unknown Fever syndrome Fever NALP12 Unknown Unknown Hydatidiform mole Hydatid mole NALP7 Unknown Unknown Vitiligo Skin depigmentation, autoimmunity NLRP1 Overactive Unknown Crohn’s disease NLRP3 Underactive Unknown Multiple Sclerosis NLPR3 Activated Unknown Psoriasitic arthritis NLRP3 Activated Yes aAnakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that functions to block the biologic activity of naturally occurring IL-1. Abbreviation: CPPD, calcium pyrophosphate dehydrate. Source: Adapted from F Martinon et al: Ann Rev Immunol 27:229, 2009. Copyright 2009. Reproduced with permission from Annual Reviews Inc. CHAPTER 342 Introduction to the Immune System 2459 B cell affinity maturation in germinal centers IL–21 IFN–γ IL–4 IL–5 IL–13 IL–17 IL–22 IL–9 T follicular helper cell TH1 cell TH2 cell Differentiation/ Activation TH17 cell TH9 cell Cytotoxic T cell responses Antibody respones; stimulate eosinophils Linked to autoimmune disease mediation IL–10 TGFβ T regulatory cell T cell function downregulation; prevent autoimmune disease CD4+ T cell T cell Lymphoid precursor Stem cell Plasmacytoid dendritic cell CD8+ Cytotoxic T cell Kill pathogen infected cells Kill tumor cells B cell Natural Killer cell Neutrophilic, eosinophilic, or basophilic granulocyte Dendritic cell Monocyte/ Macrophage Antibodies antigen presentation IFN–α antigen presentation Antibody dependent cellular cytotoxicity tumor cell killing IL–12 antigen presentation IFN–α antigen presentation IL–1, IL–6 Phagocytosis of microbes Bcl6 Tbet GATA3 RORγt PU.1 Foxp3 FIGURE 342-2 Model of immune effector cell development. Hematopoietic stem cells differentiate into T cells, antigen-presenting dendritic cells, natural killer cells, macrophages, granulocytes, or B cells. Foreign antigen is processed by dendritic cells, macrophages and B cells, and peptide fragments of foreign antigen are presented to CD4+ and/or CD8+ T cells. CD8+ T cell activation leads to induction of cytotoxic T lymphocyte (CTL) or killer T cell generation, as well as induction of cytokine-producing CD8+ cytotoxic T cells. Granulocytes (neutrophils, eosinophils, or basophils) are effector cells of the innate immune system and mediate anti infectious agent activity by cytokine production, infectious agent killing or both. TH 1 CD4+ T cells play an important role in defense against intracellular microbes and help in the generation of CD8+ cytotoxic T cells. TH 2 CD4+ T cells producing (IFN) γ or IL-4, IL-5, IL-13 regulate Ig class switching and determine the type of antibody produced. TH 17 cells secrete IL-17 and IL-22, and Th9 cells secrete IL-9. Both are linked to mediation of autoimmune disease. CD4+ T regulatory cells produce IL-10 and TGFβ and downregulate T and B cell responses once the microbe has been eliminated. Each of the types of CD4+ T cells are regulated by different transcription factors and the key transcription factors are shown in the circles above each CD4+ T cell type. PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2460 (Continued) TABLE 342-7 Cytokines and Cytokine Receptors CYTOKINE RECEPTOR CELL SOURCE CELL TARGET BIOLOGIC ACTIVITY IL-1α, β Type I IL-1r, Type II IL-1r Monocytes/macrophages, B cells, fibroblasts, most epithelial cells including thymic epithelium, endothelial cells All cells Upregulates adhesion molecule expression, neutrophil and macrophage emigration, mimics shock, fever, upregulates hepatic acute-phase protein production, facilitates hematopoiesis IL-2 IL-2r α, β, common γ T cells T cells, B cells, NK cells, monocytes-macrophages Promotes T cell activation and proliferation, B cell growth, NK cell proliferation and activation, enhanced monocyte/macrophage cytolytic activity IL-3 IL-3r, common β T cells, NK cells, mast cells Monocytes-macrophages, mast cells, eosinophils, bone marrow progenitors Stimulates hematopoietic progenitors IL-4 IL-4r α, common γ T cells, mast cells, basophils T cells, B cells, NK cells, monocytes-macrophages, neutrophils, eosinophils, endothelial cells, fibroblasts Stimulates TH 2 helper T cell differentiation and proliferation; stimulates B cell Ig class switch to IgG1 and IgE anti-inflammatory action on T cells, monocytes; produced by T follicular helper cells in B cell germinal centers that stimulate B cell maturation. IL-5 IL-5r α, common γ T cells, mast cells, eosinophils Eosinophils, basophils, murine B cells Regulates eosinophil migration and activation IL-6 IL-6r, gp130 Monocytes-macrophages, B cells, fibroblasts, most epithelium including thymic epithelium, endothelial cells T cells, B cells, epithelial cells, hepatocytes, monocytes-macrophages Induces acute-phase protein production, T and B cell differentiation and growth, myeloma cell growth, and osteoclast growth and activation IL-7 IL-7r α, common γ Bone marrow, thymic epithelial cells T cells, B cells, bone marrow cells Differentiates B, T, and NK cell precursors, activates T and NK cells IL-8 CXCR1, CXCR2 Monocytes-macrophages, T cells, neutrophils, fibroblasts, endothelial cells, epithelial cells Neutrophils, T cells, monocytes-macrophages, endothelial cells, basophils Induces neutrophil, monocyte, and T cell migration, induces neutrophil adherence to endothelial cells and histamine release from basophils, and stimulates angiogenesis; suppresses proliferation of hepatic precursors IL-9 IL-9r α, common γ T cells Bone marrow progenitors, B cells, T cells, mast cells Induces mast cell proliferation and function, synergizes with IL-4 in IgG and IgE production and T cell growth, activation, and differentiation IL-10 IL-10r Monocytes-macrophages, T cells, B cells, keratinocytes, mast cells Monocytes-macrophages, T cells, B cells, NK cells, mast cells Inhibits macrophage proinflammatory cytokine production, downregulates cytokine class II antigen and B7-1 and B7-2 expression, inhibits differentiation of TH 1 helper T cells, inhibits NK cell function, stimulates mast cell proliferation and function, B cell activation, and differentiation IL-11 IL-11r α, gp130 Bone marrow stromal cells Megakaryocytes, B cells, hepatocytes Induces megakaryocyte colony formation and maturation, enhances antibody responses, stimulates acute-phase protein production IL-12 (35-kDa and 40-kDa subunits) IL-12r Activated macrophages, dendritic cells, neutrophils T cells, NK cells Induces TH 1 T helper cell formation and lymphokine activated killer cell formation; increases CD8+ CTL cytolytic activity; ↓IL-17, ↑IFN-γ IL-13 IL-13r/IL-4r α T cells (TH 2) Monocytes-macrophages, B cells, endothelial cells, keratinocytes Upregulates VCAM-1 and C-C chemokine expression on endothelial cells and B cell activation and differentiation, and inhibits macrophage proinflammatory cytokine production IL-14 Unknown T cells Normal and malignant B cells Induces B cell proliferation, inhibits antibody secretion, and expands selected B cell subgroups IL-15 IL-15r α, common γ, IL2r β Monocytes-macrophages, epithelial cells, fibroblasts T cells, NK cells Promotes T cell activation and proliferation, angiogenesis, and NK cells IL-16 CD4 Mast cells, eosinophils, CD8+ T cells, respiratory epithelium CD4+ T cells, monocytes- macrophages, eosinophils Promotes chemoattraction of CD4+ T cells, monocytes, and eosinophils; inhibits HIV replication; inhibits T cell activation through CD3/T cell receptor IL-17 IL-17r CD4+ T cells Fibroblasts, endothelium, epithelium, macrophages Enhances cytokine/chemokine secretion; promotes delayed-type reactions IL-18 IL-18r (IL-1R-related protein) Keratinocytes, macrophages T cells, B cells, NK cells Upregulates IFN-γ production, enhances NK cell cytotoxicity IL-21 IL-δγ chain/IL-21R CD4 T cells NK cells Downregulates NK cell–activating molecules, NKG2D/DAP10; produced by T follicular helper cells in B cell germinal centers that stimulate B cell maturation. IL-22 IL-22 R1/IL-10R2 DC, T cells Epithelial cells Innate responses against bacterial pathogens; promotes hepatocyte survival IL-23 IL-12Rb1/IL23R Macrophages, other cell types T cells Opposite effects of IL-12 (↑IL-17, ↑IFN-γ) IL-24 IL-20 R1/IL-20R2 IL-22R1/IL-20 R2 Macrophages, TH 2 cells Nonhematopoietic cells such as fibroblasts Promotes wound healing CHAPTER 342 Introduction to the Immune System 2461 TABLE 342-7 Cytokines and Cytokine Receptors CYTOKINE RECEPTOR CELL SOURCE CELL TARGET BIOLOGIC ACTIVITY IL-25 (also called IL-17E) IL-17RB CD4 T cells, mast cells Fibroblasts, endothelium, epithelium, macrophages Proinflammatory; induces cytokine production IL-26 IL-20 R1/IL-10R2 TH 1, TH 17 T cells, synovial cells Epithelial cells Proinflammatory; induces cytokine production IFN-α Type I interferon receptor All cells All cells Promotes antiviral activity; stimulates T cell, macrophage, and NK cell activity; direct antitumor effects; upregulates MHC class I antigen expression; used therapeutically in viral and autoimmune conditions IFN-β Type I interferon receptor All cells All cells Antiviral activity; stimulates T cell, macrophage, and NK cell activity; direct antitumor effects; upregulates MHC class I antigen expression; used therapeutically in viral and autoimmune conditions IFN-γ Type II interferon receptor T cells, NK cells All cells Regulates macrophage and NK cell activations; stimulates immunoglobulin secretion by B cells; induction of class II histocompatibility antigens; TH 1 T cell differentiation TNF-α TNFrI, TNFrII Monocytes-macrophages, mast cells, basophils, eosinophils, NK cells, B cells, T cells, keratinocytes, fibroblasts, thymic epithelial cells All cells except erythrocytes Fever, anorexia, shock, capillary leak syndrome, enhanced leukocyte cytotoxicity, enhanced NK cell function, acute phase protein synthesis, proinflammatory cytokine induction TNF-β TNFrI, TNFrII T cells, B cells All cells except erythrocytes Cell cytotoxicity, lymph node and spleen development LT-β LTβR T cells All cells except erythrocytes Cell cytotoxicity, normal lymph node development G-CSF G-CSFr; gp130 Monocytes-macrophages, fibroblasts, endothelial cells, thymic epithelial cells, stromal cells Myeloid cells, endothelial cells Regulates myelopoiesis; enhances survival and function of neutrophils; clinical use in reversing neutropenia after cytotoxic chemotherapy GM-CSF GM-CSFr, common β T cells, monocytes macrophages, fibroblasts, endothelial cells, thymic epithelial cells Monocytes-macrophages, neutrophils, eosinophils, fibroblasts, endothelial cells Regulates myelopoiesis; enhances macrophage bactericidal and tumoricidal activity; mediator of dendritic cell maturation and function; upregulates NK cell function; clinical use in reversing neutropenia after cytotoxic chemotherapy M-CSF M-CSFr (c-fms protooncogene) Fibroblasts, endothelial cells, monocytes-macrophages, T cells, B cells, epithelial cells including thymic epithelium Monocytes-macrophages Regulates monocyte-macrophage production and function LIF LIFr-α; gp130 Activated T cells, bone marrow stromal cells, thymic epithelium Megakaryocytes, monocytes, hepatocytes, possibly lymphocyte subpopulations Induces hepatic acute-phase protein production; stimulates macrophage differentiation; promotes growth of myeloma cells and hematopoietic progenitors; stimulates thrombopoiesis OSM OSMr; LIFr; gp130 Activated monocytes macrophages and T cells, bone marrow stromal cells, some breast carcinoma cell lines, myeloma cells Neurons, hepatocytes, monocytes-macrophages, adipocytes, alveolar epithelial cells, embryonic stem cells, melanocytes, endothelial cells, fibroblasts, myeloma cells Induces hepatic acute-phase protein production; stimulates macrophage differentiation; promotes growth of myeloma cells and hematopoietic progenitors; stimulates thrombopoiesis; stimulates growth of Kaposi’s sarcoma cells SCF SCFr (c-kit protooncogene) Bone marrow stromal cells and fibroblasts Embryonic stem cells, myeloid and lymphoid precursors, mast cells Stimulates hematopoietic progenitor cell growth, mast cell growth; promotes embryonic stem cell migration TGF-β (3 isoforms) Type I, II, III TGF-β receptor Most cell types Most cell types Downregulates T cell, macrophage, and granulocyte responses; stimulates synthesis of matrix proteins; stimulates angiogenesis Lymphotactin/ SCM-1 XCR1 NK cells, mast cells, double-negative thymocytes, activated CD8+ T cells T cells, NK cells Chemoattractant for lymphocytes; only known chemokine of C class MCP-1 CCR2 Fibroblasts, smooth-muscle cells, activated PBMCs Monocytes-macrophages, NK cells, memory T cells, basophils Chemoattractant for monocytes, activated memory T cells, and NK cells; induces granule release from CD8+ T cells and NK cells; potent histamine releasing factor for basophils; suppresses proliferation of hematopoietic precursors; regulates monocyte protease production MCP-2 CCR1, CCR2 Fibroblasts, activated PBMCs Monocytes-macrophages, T cells, eosinophils, basophils, NK cells Chemoattractant for monocytes, memory and naïve T cells, eosinophils, ?NK cells; activates basophils and eosinophils; regulates monocyte protease production MCP-3 CCR1, CCR2 Fibroblasts, activated PBMCs Monocytes-macrophages, T cells, eosinophils, basophils, NK cells, dendritic cells Chemoattractant for monocytes, memory and naïve T cells, dendritic cells, eosinophils, ?NK cells; activates basophils and eosinophils; regulates monocyte protease production (Continued) (Continued) PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2462 TABLE 342-7 Cytokines and Cytokine Receptors CYTOKINE RECEPTOR CELL SOURCE CELL TARGET BIOLOGIC ACTIVITY MCP-4 CCR2, CCR3 Lung, colon, small intestinal epithelial cells, activated endothelial cells Monocytes-macrophages, T cells, eosinophils, basophils Chemoattractant for monocytes, T cells, eosinophils, and basophils Eotaxin CCR3 Pulmonary epithelial cells, heart Eosinophils, basophils Potent chemoattractant for eosinophils and basophils; induces allergic airways disease; acts in concert with IL-5 to activate eosinophils; antibodies to eotaxin inhibit airway inflammation TARC CCR4 Thymus, dendritic cells, activated T cells T cells, NK cells Chemoattractant for T and NK cells MDC CCR4 Monocytes-macrophages, dendritic cells, thymus Activated T cells Chemoattractant for activated T cells; inhibits infection with T cell tropic HIV MIP-1α CCR1, CCR5 Monocytes-macrophages, T cells Monocytes-macrophages, T cells, dendritic cells, NK cells, eosinophils, basophils Chemoattractant for monocytes, T cells, dendritic cells, and NK cells, and weak chemoattractant for eosinophils and basophils; activates NK cell function; suppresses proliferation of hematopoietic precursors; necessary for myocarditis associated with coxsackievirus infection; inhibits infection with monocytotropic HIV MIP-1β CCR5 Monocytes-macrophages, T cells Monocytes-macrophages, T cells, NK cells, dendritic cells Chemoattractant for monocytes, T cells, and NK cells; activates NK cell function; inhibits infection with monocytotropic HIV RANTES CCR1, CCR2, CCR5 Monocytes-macrophages, T cells, fibroblasts, eosinophils Monocytes-macrophages, T cells, NK cells, dendritic cells, eosinophils, basophils Chemoattractant for monocytes-macrophages, CD4+, CD45Ro+ T cells, CD8+ T cells, NK cells, eosinophils, and basophils; induces histamine release from basophils; inhibits infections with monocytotropic HIV LARC/MIP-3α/ Exodus-1 CCR6 Dendritic cells, fetal liver cells, activated T cells T cells, B cells Chemoattractant for lymphocytes ELC/MIP-3β CCR7 Thymus, lymph node, appendix Activated T cells and B cells Chemoattractant for B and T cells; receptor upregulated on EBV-infected B cells and HSV-infected T cells I-309/TCA-3 CCR8 Activated T cells Monocytes-macrophages, T cells Chemoattractant for monocytes; prevents glucocorticoid-induced apoptosis in some T cell lines SLC/TCA-4/ Exodus-2 CCR7 Thymic epithelial cells, lymph node, appendix, and spleen T cells Chemoattractant for T lymphocytes; inhibits hematopoiesis DC-CK1/PARC Unknown Dendritic cells in secondary lymphoid tissues Naïve T cells May have a role in induction of immune responses TECK CCR9 Dendritic cells, thymus, liver, small intestine T cells, monocytes macrophages, dendritic cells Thymic dendritic cell-derived cytokine, possibly involved in T cell development GRO-α/MGSA CXCR2 Activated granulocytes, monocyte-macrophages, and epithelial cells Neutrophils, epithelial cells, ?endothelial cells Neutrophil chemoattractant and activator; mitogenic for some melanoma cell lines; suppresses proliferation of hematopoietic precursors; angiogenic activity GRO-β/MIP-2α CXCR2 Activated granulocytes and monocyte-macrophages Neutrophils and ?endothelial cells Neutrophil chemoattractant and activator; angiogenic activity NAP-2 CXCR2 Platelets Neutrophils, basophils Derived from platelet basic protein; neutrophil chemoattractant and activator IP-10 CXCR3 Monocytes-macrophages, T cells, fibroblasts, endothelial cells, epithelial cells Activated T cells, tumor infiltrating lymphocytes, ?endothelial cells, ?NK cells IFN-γ-inducible protein that is a chemoattractant for T cells; suppresses proliferation of hematopoietic precursors MIG CXCR3 Monocytes-macrophages, T cells, fibroblasts Activated T cells, tumor infiltrating lymphocytes IFN-γ-inducible protein that is a chemoattractant for T cells; suppresses proliferation of hematopoietic precursors SDF-1 CXCR4 Fibroblasts T cells, dendritic cells, ?basophils, ?endothelial cells Low-potency, high-efficacy T cell chemoattractant; required for B-lymphocyte development; prevents infection of CD4+, CXCR4+ cells by T cell tropic HIV Fractalkine CX3CR1 Activated endothelial cells NK cells, T cells, monocytes-macrophages Cell-surface chemokine/mucin hybrid molecule that functions as a chemoattractant, leukocyte activator, and cell adhesion molecule PF-4 Unknown Platelets, megakaryocytes Fibroblasts, endothelial cells Chemoattractant for fibroblasts; suppresses proliferation of hematopoietic precursors; inhibits endothelial cell proliferation and angiogenesis Abbreviations: B7-1, CD80; B7-2, CD86; CCR, CC-type chemokine receptor; CXCR, CXC-type chemokine receptor; DC-CK, dendritic cell chemokine; EBV, Epstein-Barr virus; ELC, EB11 ligand chemokine (MIP-1b); G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; GRP, growth-related peptide; HSV, herpes simplex virus; IFN, interferon; Ig, immunoglobulin; IL, interleukin; IP-10, IFN-γ-inducible protein-10; LARC, liver- and activation-regulated chemokine; LIF, leukemia inhibitory factor; MCP, monocyte chemotactic protein; M-CSF, macrophage colony-stimulating factor; MDC, macrophage-derived chemokine; MGSA, melanoma growth-stimulating activity; MHC, major histocompatibility complex; MIG, monokine induced by IFN-γ; MIP, macrophage inflammatory protein; NAP, neutrophil activating protein; NK, natural killer; OSM, oncostatin M; PARC, pulmonary- and activation-regulated chemokine; PBMC, peripheral blood mononuclear cells; PF, platelet factor; RANTES, regulated on activation, normally T cell–expressed and –secreted; SCF, stem cell factor; SDF, stromal cell–derived factor; SLC, secondary lymphoid tissue chemokine; TARC, thymus- and activation-regulated chemokine; TCA, T cell activation protein; TECK, thymus-expressed chemokine; TGF, transforming growth factor; TH 1 and TH 2, helper T cell subsets; TNF, tumor necrosis factor; VCAM, vascular cell adhesion molecule. Source: Data from JS Sundy et al: Appendix B, in Inflammation, Basic Principles and Clinical Correlates, 3rd ed, J Gallin and R Snyderman (eds). Philadelphia, Lippincott Williams and Wilkins, 1999. (Continued) CHAPTER 342 Introduction to the Immune System 2463 eosinophil granule contains anti-inflammatory types of enzymes (histaminase, arylsulfatase, phospholipase D), eosinophils may homeo statically downregulate or terminate ongoing inflammatory responses. Basophils and tissue mast cells are potent reservoirs of cytokines such as IL-4 and can respond to bacteria and viruses with antipatho gen cytokine production through multiple TLRs expressed on their surface. Mast cells and basophils can also mediate immunity through the binding of antipathogen antibodies. This is a particularly impor tant host defense mechanism against parasitic diseases. Basophils express high-affinity surface receptors for IgE (FcεRII) (CD23) and, upon cross-linking of basophil-bound IgE by antigen, can release histamine, eosinophil chemotactic factor of anaphylaxis, and neutral protease—all mediators of allergic immediate (anaphylaxis) hypersen sitivity responses (Table 342-11). In addition, basophils express surface receptors for activated complement components (C3a, C5a), through which mediator release can be directly affected. Thus, basophils, like most cells of the immune system, can be activated in the service of host defense against pathogens, or they can be activated for mediation release and cause pathogenic responses in allergic and inflammatory diseases. For further discussion of tissue mast cells, see Chap. 347. The Complement System The complement system, an impor tant soluble component of the innate immune system, is a series of plasma enzymes, regulatory proteins, and proteins that are activated in a cascading fashion, resulting in cell lysis. There are four pathways of the complement system: the classic activation pathway activated by antigen/antibody immune complexes, the MBL (a serum collectin; Table 342-3) activation pathway activated by microbes with terminal mannose groups, the alternative activation pathway activated by microbes or tumor cells, and the terminal pathway that is common to the first three pathways and leads to the membrane attack complex that lyses cells (Fig. 342-4). The series of enzymes of the complement system are serine proteases. Activation of the classic complement pathway via immune complex binding to C1q links the innate and adaptive immune systems via specific antibody in the immune complex. The alternative comple ment activation pathway is antibody-independent and is activated by binding of C3 directly to pathogens and “altered self” such as tumor cells. In the renal glomerular inflammatory disease IgA nephropathy, IgA activates the alternative complement pathway and causes glom erular damage and decreased renal function. Activation of the classic TABLE 342-8 CC, CXC1 , CX3 , C1 , and XC Families of Chemokines and Chemokine Receptors CHEMOKINE RECEPTOR CHEMOKINE LIGANDS CELL TYPES DISEASE CONNECTION CCR1 CCL3 (MIP-1α), CCL5 (RANTES), CCL7 (MCP-3), CCL14 (HCC1) T cells, monocytes, eosinophils, basophils Rheumatoid arthritis, multiple sclerosis CCR2 CCL2 (MCP-1), CCL8 (MCP-2), CCL7 (MCP-3), CCL13 (MCP-4), CCL16 (HCC4) Monocytes, dendritic cells (immature), memory T cells Atherosclerosis, rheumatoid arthritis, multiple sclerosis, resistance to intracellular pathogens, type 2 diabetes mellitus CCR3 CCL11 (eotaxin), CCL13 (eotaxin-2), CCL7 (MCP-3), CCL5 (RANTES), CCL8 (MCP-2), CCL13 (MCP-4) Eosinophils, basophils, mast cells, TH 2, platelets Allergic asthma and rhinitis CCR4 CCL17 (TARC), CCL22 (MDC) T cells (TH 2), dendritic cells (mature), basophils, macrophages, platelets Parasitic infection, graft rejection, T cell homing to skin CCR5 CCL3 (MIP-1α), CCL4 (MIP-1α), CCL5 (RANTES), CCL11 (eotaxin), CCL14 (HCC1), CCL16 (HCC4) T cells, monocytes HIV-1 co-receptor (T cell–tropic strains), transplant rejection CCR6 CCL20 (MIP-3α, LARC) T cells (T regulatory and memory), B cells, dendritic cells Mucosal humoral immunity, allergic asthma, intestinal T cell homing CCR7 CCL19 (ELC), CCL21 (SLC) T cells, dendritic cells (mature) Transport of T cells and dendritic cells to lymph nodes, antigen presentation, and cellular immunity CCR8 CCL1 (1309) T cells (TH 2), monocytes, dendritic cells Dendritic cell migration to lymph node, type 2 cellular immunity, granuloma formation CCR9 CCL25 (TECK) T cells, IgA+ plasma cells Homing of T cells and IgA+ plasma cells to the intestine, inflammatory bowel disease CCR10 CCL27 (CTACK), CCL28 (MEC) T cells T cell homing to intestine and skin CXCR1 CXCL8 (interleukin-8), CXCL6 (GCP2) Neutrophils, monocytes Inflammatory lung disease, COPD CXCR2 CXCL8, CXCL1 (GROα), CXCL2 (GROα), CXCL3 (GROα), CXCL5 (ENA-78), CXCL6 Neutrophils, monocytes, microvascular endothelial cells Inflammatory lung disease, COPD, angiogenic for tumor growth CXCR3-A CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC) Type 1 helper cells, mast cells, mesangial cells Inflammatory skin disease, multiple sclerosis, transplant rejection CXCR3-B CXCL4 (PF4), CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC) Microvascular endothelial cells, neoplastic cells Angiostatic for tumor growth CXCR4 CXCL12 (SDF-1) Widely expressed HIV-1 co-receptor (T cell–tropic), tumor metastases, hematopoiesis CXCR5 CXCL13 (BCA-1) B cells, follicular helper T cells Formation of B cell follicles CXCR6 CXCL16 (SR-PSOX) CD8+ T cells, natural killer cells, and memory CD4+ T cells Inflammatory liver disease, atherosclerosis (CXCL16) CX3 CR1 CX3CL1 (fractalkine) Macrophages, endothelial cells, smooth-muscle cells Atherosclerosis XCR1 XCL1 (lymphotactin), XCL2 T cells, natural killer cells Rheumatoid arthritis, IgA nephropathy, tumor response Abbreviations: BCA-1, B-cell chemoattractant 1; COPD, chronic obstructive pulmonary disease; CTACK, cutaneous T cell–attracting chemokine; ELC, Epstein- Barr I1-ligand chemokine; ENA, epithelial cell–derived neutrophil-activating peptide; GCP, granulocyte chemotactic protein; GRO, growth-regulated oncogene; HCC, hemofiltrate chemokine; IP-10, interferon inducible 10; I-TAC, interferon-inducible T cell alpha chemoattractant; LARC, liver- and activation-regulated chemokine; MCP, monocyte chemoattractant protein; MDC, macrophage-derived chemokine; MEC, mammary-enriched chemokine; MIG, monokine induced by interferon-γ; MIP, macrophage inflammatory protein; PF, platelet factor; SDF, stromal cell–derived factor; SLC, secondary lymphoid-tissue chemokine; SR-PSOX, scavenger receptor for phosphatidylserine-containing oxidized lipids; TARC, thymus- and activation-regulated chemokine; TECK, thymus-expressed chemokine; TH 2, type 2 helper T cells. Source: From IF Charo, RM Ranshohoff: N Engl J Med 354:610, 2006, with permission. Copyright Massachusetts Medical Society. All rights reserved. PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2464 TABLE 342-9 Cytokine Families Grouped by Structural Similarity Hematopoietins IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, IL-16, IL-17, IL-21, IL-23, EPO, LIF, GM-CSF, G-CSF, OSM, CNTF, GH, and TPO TNF-α, LT-α, LT-β, CD40L, CD30L, CD27L, 4-1BBL, OX40, OPG, and FasL IL-1 IL-1α, IL-1β, IL-1ra, IL-18, bFGF, aFGF, and ECGF PDGF PDGF A, PDGF B, and M-CSF TGF-β TGF-β and BMPs (1, 2, 4, etc.) C-X-C chemokines IL-8, Gro-α/β/γ, NAP-2, ENA78, GCP-2, PF4, CTAP-3, MIG, and IP-10 C-C chemokines MCP-1, MCP-2, MCP-3, MIP-1α, MIP-1β, RANTES Abbreviations: aFGF, acidic fibroblast growth factor; 4-1BBL, 401 BB ligand; bFGF, basic fibroblast growth factor; BMP, bone marrow morphogenetic proteins; C-C, cysteine-cysteine; CD, cluster of differentiation; CNTF, ciliary neurotrophic factor; CTAP, connective tissue–activating peptide; C-X-C, cysteine-x-cysteine; ECGF, endothelial cell growth factor; EPO, erythropoietin; FasL, Fas ligand; GCP-2, granulocyte chemotactic protein 2; G-CSF, granulocyte colony-stimulating factor; GH, growth hormone; GM-CSF, granulocyte-macrophage colony-stimulating factor; Gro, growth-related gene products; IFN, interferon; IL, interleukin; IP, interferon-γ inducible protein; LIF, leukemia inhibitory factor; LT, lymphotoxin; MCP, monocyte chemoattractant; M-CSF, macrophage colony-stimulating factor; MIG, monokine induced by interferon-γ; MIP, macrophage inflammatory protein; NAP-2, neutrophil activating protein 2; OPG, osteoprotegerin; OSM, oncostatin M; PDGF, platelet derived growth factor; PF, platelet factor; R, receptor; RANTES, regulated on activation, normal T cell–expressed and –secreted; TGF, transforming growth factor; TNF, tumor necrosis factor; TPO, thyroperoxidase. TABLE 342-10 Association of KIRS with Disease DISEASE KIR ASSOCIATION OBSERVATION Psoriatic arthritis KIR2DS1/KIR2DS2; HLA-Cw group homozygosity Susceptibility Spondylarthritides Increased KIR3DL2 expression Interaction HLA-B27 homodimers with KIR3DL1/KIR3DL2; independent of peptide May contribute to disease pathology May contribute to disease pathogenesis Ankylosing spondylitis KIR3DL1/3DS1; HLA-B27 genotypes Susceptibility Rheumatoid vasculitis KIR2DS2; HLA-Cw03 Increased KIR2L2/2DS2 in patients with extraarticular manifestations Susceptibility Clinical manifestations may have different genetic backgrounds with respect to KIR genotype Rheumatoid arthritis Decreased KIR2DS1/3DS1 in patients without bone erosions KIR2DS4; HLA-Cw4 Susceptibility Susceptibility Scleroderma KIR2DS2+/KIR2DL2–Susceptibility Behçet’s disease Altered KIR3DL1 expression Associated with severe eye disease Psoriasis vulgaris 2DS1; HLA-Cw06 2DS1; 2DL5; haplotype B Susceptibility Susceptibility IDDM KIR2DS2; HLA-C1 Susceptibility Type 1 diabetes KIR2DS2; HLA-C1 and no HLA-C2, no HLA-Bw4 Increased disease progression Preeclampsia KIR2DL1 with fewer KIR2DS (mother); HLA-C2 (fetus) Increased disease progression AIDS KIR3DS1; HLA-Bw4Ile80 KIR3DS1 homozygous; no HLA-Bw4Ile80 Decreased disease progression Increased disease progression HCV infection KIR2DL3 homozygous; HLA-C1 homozygous Decreased disease progression Cervical neoplasia (HPV induced) KIR3DS1; HLA-C1 homozygous and no HLA-Bw4 Increased disease progression Malignant melanoma KIR2DL2 and/or KIR2DL3; HLA-C1 Increased disease progression Abbreviations: HCV, hepatitis C virus; HLA, human leukocyte antigen; HPV, human papillomavirus; IDDM, insulin-dependent diabetes mellitus; KIR, killer cell immunoglobulin-like receptor. Source: Adapted from R Diaz-Pena et al: Adv Exp Med Biol 649:286, 2009. complement pathway via C1, C4, and C2 and activation of the alter native pathway via factor D, C3, and factor B both lead to cleavage and activation of C3. C3 activation fragments, when bound to target surfaces such as bacteria and other foreign antigens, are critical for opsonization (coating by antibody and complement) in preparation for phagocytosis. The MBL pathway substitutes MBL-associated serine proteases (MASPs) 1 and 2 for C1q, C1r, and C1s to activate C4. The MBL activation pathway is activated by mannose on the surface of bacteria and viruses. The three pathways of complement activation all converge on the final common terminal pathway. C3 cleavage by each pathway results in activation of C5, C6, C7, C8, and C9, resulting in the membrane attack complex that physically inserts into the membranes of target cells or bacteria and lyses them. Thus, complement activation is a critical component of innate immunity for responding to microbial infection. The functional conse quences of complement activation by the three initiating pathways and the terminal pathway are shown in Fig. 342-4. In general, the cleavage products of complement components facilitate microbe or damaged cell clearance (C1q, C4, C3), promote activation and enhancement of inflammation (anaphylatoxins, C3a, C5a), and promote microbe or opsonized cell lysis (membrane attack complex). ■CYTOKINES Cytokines are soluble proteins produced by a wide variety of cell types (Tables 342-7 to 342-9). They are critical for both normal innate and adaptive immune responses, and their expression may be perturbed in most immune, inflammatory, and infectious disease states. Cytokines are involved in the regulation of the growth, develop ment, and activation of immune system cells and in the mediation of the inflammatory response. In general, cytokines are characterized by considerable redundancy; different cytokines have similar functions. In addition, many cytokines are pleiotropic in that they are capable of acting on many different cell types. This pleiotropism results from the expression on multiple cell types of receptors for the same cytokine (see below), leading to the formation of “cytokine networks.” The action of cytokines may be (1) autocrine when the target cell is the same cell that secretes the cytokine, (2) paracrine when the target cell is nearby, and (3) endocrine when the cytokine is secreted into the circulation and acts distal to the source. Cytokines have been named based on presumed targets or based on presumed functions. Those cytokines that are thought to primarily tar get leukocytes have been named IL-1, 2, 3, etc. Many cytokines that were originally described as having a certain function have retained those Inhibitory receptor No response 2465 A NK Activating receptor No HLA class I No activating ligands Target B C D NK NK NK HLA class I No activating ligands Target No HLA class I Activating ligands Target HLA class I Activating ligands Target FIGURE 342-3 Encounters between NK cells: Potential targets and possible outcomes. The amount of activating and inhibitory receptors on the NK cells and the amount of ligands on the target cell, as well as the qualitative differences in the signals transduced, determine the extent of the NK response. A. When target cells have no HLA class I or activating ligands, NK cells cannot kill target cells. B. When target cells bear self-HLA, NK cells cannot kill targets. C. When target cells are pathogen-infected and have downregulated HLA and express activating ligands, NK cells kill target cells. D. When NK cells encounter targets with both self-HLA and activating receptors, then the level of target killing is determined by the balance of inhibitory and activating signals to the NK cell. HLA, human leukocyte antigen; NK, natural killer. (Adapted from L Lanier: Annu Rev Immunol 23:225, 2005; reproduced with permission from Annual Reviews Inc. Copyright 2011 by Annual Reviews Inc.) TABLE 342-11 Examples of Mediators Released from Immune Cells and Basophils MEDIATOR Histamine Slow reacting substance of anaphylaxis (SRSA) (leukotriene C4 , D4 , E4 ) Eosinophil chemotactic factor of anaphylaxis (ECF-A) Platelet-activating factor Neutrophil chemotactic factor (NCF) Leukotactic activity (leukotriene B4 ) Heparin ACTIONS Smooth-muscle contraction, increased vascular permeability Smooth-muscle contraction Chemotactic attraction of eosinophils Activates platelets to secrete serotonin and other mediators: smooth-muscle contraction; induces vascular permeability Chemotactic attraction of neutrophils Chemotactic attraction of neutrophils Anticoagulant Basophil kallikrein of anaphylaxis (BK-A) Cleaves kininogen to form bradykinin Classic activation pathway Antigen/antibody immune complex C1q-C1r-C1s C4 Mannose-binding lectin activation pathway Microbes with terminal mannose groups MBL-MASP1-MASP2 C4 Alternative activation pathway Bacteria, fungi, virus, or tumor cells C3 (H2O) B D C2 No response NK attacks target cells Outcome determined by balance of signals Immune complex modification Clearance of apoptotic cells Terminal pathway C2 C3 C3b C5 C6 C7 C8 poly-C9 P Anaphylatoxin Opsonin Lymphocyte activation Anaphylatoxin Lysis CHAPTER 342 Introduction to the Immune System Membrane perturbation FIGURE 342-4 The four pathways and the effector mechanisms of the complement system. Dashed arrows indicate the functions of pathway components. (After BJ Morley, MJ Walport: The Complement Facts Books. London, Academic Press, 2000, Chap. 2; with permission. Copyright Academic Press, London, 2000.) names (e.g., granulocyte colony-stimulating factor [G-CSF]). Cytokines belong in general to three major structural families: the hematopoie tin family; the TNF, IL-1, platelet-derived growth factor (PDGF), and transforming growth factor (TGF) β families; and the CXC and C-C chemokine families (Table 342-9). Chemokines are cytokines that regu late cell movement and trafficking; they act through G protein-coupled receptors and have a distinctive three-dimensional structure. IL-8 is the only chemokine that early on was named an IL (Table 342-7). In general, cytokines exert their effects by influencing gene activation that results in cellular activation, growth, differentiation, functional cell-surface molecule expression, and cellular effector function. In this regard, cytokines can have dramatic effects on the regulation of immune responses and the pathogenesis of a variety of diseases. Indeed, T cells have been categorized on the basis of the pattern of cytokines that they secrete, which results in either humoral immune response (TH 2) or cell-mediated immune response (TH 1). A third type of T helper cell is the TH 17 cell that contributes to host defense against extracellular bacteria and fungi, particularly at mucosal sites (Fig. 342-2). Cytokine receptors can be grouped into five general families based on similarities in their extracellular amino acid sequences and conserved structural domains. The immunoglobulin (Ig) superfamily represents a large number of cell-surface and secreted proteins. The IL-1 receptors (type 1, type 2) are examples of cytokine receptors with extracellular Ig domains. The hallmark of the hematopoietic growth factor (type 1) receptor family is that the extracellular regions of each receptor contain two conserved motifs. One motif, located at the N terminus, is rich in cysteine residues. The other motif is located at the C terminus proximal to the transmembrane region and comprises five amino acid residues, tryptophan-serine-X-tryptophan-serine (WSXWS). This family can be grouped on the basis of the number of receptor subunits they have and on the utilization of shared subunits. A number of cytokine receptors, i.e., IL-6, IL-11, IL-12, and leukemia inhibitory factor, are paired with gp130. There is also a common 150-kDa subunit shared by IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors. The gamma chain (γc ) of the IL-2 receptor is common to the IL-2, IL-4, IL-7, IL-9, and IL-15 receptors. Thus, the specific cytokine receptor is translocate to the nucleus, bind to DNA motifs that they recognize, and regulate gene expression. The STATs preferentially bind DNA motifs that are slightly different from one another and thereby control transcription of specific genes. The importance of this pathway is particularly relevant to lymphoid development. Mutations of JAK3 itself also result in a disorder identical to X-SCID; however, because JAK3 is found on chromosome 19 and not on the X chromosome, JAK3 deficiency occurs in boys and girls (Chap. 344). Thymus medulla and peripheral T cell pools ■THE ADAPTIVE IMMUNE SYSTEM Adaptive immunity is characterized by antigen-specific responses to a foreign antigen or pathogen. A key feature of adaptive immunity is that following the initial contact with antigen (immunologic priming), sub sequent antigen exposure leads to more rapid and vigorous immune responses (immunologic memory). The adaptive immune system con sists of dual limbs of cellular and humoral immunity. The principal effectors of cellular immunity are T lymphocytes, whereas the prin cipal effectors of humoral immunity are B lymphocytes. Both B and T lymphocytes derive from a common stem cell (Fig. 342-5). CD7 CD2 CD3, TCRαβ CD4 CD7 CD2 CD3, TCRαβ CD8 Mature T mmature T Mature T ro-T Pro-T I CD7 CD2 cCD3, TCRαβ CD1 CD4, CD8 Mature T IgM Mature B cell IgD VDJ rearranged VJ rearranged IgD and IgM made from alternatively spliced H-chain transcripts CD7 CD2 CD3, TCRγδ CD8 Immature B cell α-VJ Rearranged β- VDJ Rearranged Small pre-B cell Pro-T P CD7 CD2 CD3 α- Germline β- VDJ Rearranged CD34+ CD7lo+ or α,β Germline CD34+ Hematopoietic α,β Germline Large pre-B cell Late pro-B cell Early pro-B cell Hematopoietic stem cell CD34+ VDJ rearranged VJ rearranged IgM expressed on cell surface VDJ rearranged VJ rearranging µ H-chain in cytoplasm VDJ rearranged Germline µ H-chain at surface as part of the Pre-B receptor (orange) containing surrogate light chain (SLC). Receptor is mainly intra cellular VDJ rearranging Germline Absent D-J rearranging Germline Absent Heavy-chain genes Light-chain genes CD19 CD20 CD21 CD19 CD20 CD19 CD20 CD38 CD19 CD20 CD38 CD10 CD19 CD38 CD40 CD34 CD10 CD38 FIGURE 342-5 Development stages of T and B cells. Elements of the developing T and B cell receptor for antigen are shown schematically. The classi cation into the various stages of B cell development is primarily dened by rearrangement of the immunoglobulin (Ig) heavy (H) and light (L) chain genes and by the absence or presence of speci c surface markers. The classi cation of stages of T cell development is primarily dened by cell-surface marker protein expression (sCD3, surface CD3 expression; cCD3, cytoplasmic CD3 expression; TCR, T cell receptor). For B cell development, the pre-B cell receptor is shown as a blue-orange B cell receptor. (Adapted from CA Janeway et al [eds]: Immunobiology, 9th ed. New York, Garland, 2016; with permission.) 2466 responsible for ligand-specific binding, whereas the subunits such as gp130, the 150-kDa subunit, and γc are important in signal transduction. The γc gene is on the X chromosome, and mutations in the γc protein result in the X-linked form of severe combined immune deficiency syndrome (X-SCID) (Chap. 344). The members of the interferon (type II) receptor family include the receptors for IFN-γ and β, which share a similar 210-amino-acid binding domain with conserved cysteine pairs at both the amino and carboxy termini. The members of the TNF (type III) receptor family share a common binding domain composed of repeated cysteine-rich regions. Members of this family include the p55 and p75 receptors for TNF (TNF-R1 and TNF-R2, respectively); CD40 antigen, which is an important B cell-surface marker involved in immunoglobulin isotype switching; fas/Apo-1, whose triggering induces apoptosis; CD27 and CD30, which are found on activated T cells and B cells; and nerve growth factor receptor. The common motif for the seven transmembrane helix family was originally found in receptors linked to GTP-binding proteins. This family includes receptors for chemokines (Table 342-8), β-adrenergic receptors, and retinal rhodopsin. It is important to note that two members of the chemokine receptor family, CXC chemokine receptor type 4 (CXCR4) and β chemokine receptor type 5 (CCR5), have been found to serve as the two major co-receptors for binding and entry of HIV into CD4-expressing host cells (Chap. 197). Significant advances have been made in defining the signaling path ways through which cytokines exert their intracellular effects. The Janus family of protein tyrosine kinases (JAK) is a critical element involved in signaling via the hematopoietin recep tors. Four JAK kinases, JAK1, JAK2, JAK3, and Tyk2, preferentially bind different cytokine receptor subunits. Cytokine binding to its receptor brings the cytokine receptor subunits into apposition and allows a pair of JAKs to transphosphorylate and activate one another. The JAKs then phosphorylate the receptor on the tyrosine residues and allow signaling molecules to bind to the receptor, whereby the signaling molecules become phosphorylated. Signaling molecules bind the receptor because they have domains (SH2, or src homology 2 domains) that can bind phosphorylated tyrosine residues. There are a number of these impor tant signaling molecules that bind the receptor, such as the adapter molecule SHC, which can couple the recep tor to the activation of the mitogen- activated protein kinase pathway. In addition, an important class of sub strate of the JAKs is the signal trans ducers and activators of transcription (STAT) family of transcription factors. STATs have SH2 domains that enable them to bind to phosphorylated recep tors, where they are then phospho rylated by the JAKs. It appears that different STATs have specificity for different receptor subunits. The STATs then dissociate from the receptor and Surface Ig PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders Surface marker proteins 2467 The proportion and distribution of immunocompetent cells in various tissues reflect cell traffic, homing patterns, and functional capabilities. Bone marrow is the major site of maturation of B cells, monocytes-macrophages, DCs, and granulocytes and contains pluripo tent stem cells that, under the influence of various colony-stimulating factors, are capable of giving rise to all hematopoietic cell types. T cell precursors also arise from hematopoietic stem cells and home to the thymus for maturation. Mature T lymphocytes, B lymphocytes, mono cytes, and DCs enter the circulation and home to peripheral lymphoid organs (lymph nodes, spleen) and mucosal surface-associated lym phoid tissue (gut, genitourinary, and respiratory tracts) as well as the skin and mucous membranes and await activation by foreign antigen. T Cells The pool of effector T cells is established in the thymus early in life and is maintained throughout life both by new T cell production in the thymus and by antigen-driven expansion of virgin peripheral T cells into “memory” T cells that reside in peripheral lymphoid organs. The thymus exports ~2% of the total number of thymocytes per day throughout life, with the total number of daily thymic emigrants decreasing by ~3% per year during the first four decades of life. Mature T lymphocytes constitute 70–80% of normal peripheral blood lymphocytes (only 2% of the total-body lymphocytes are con tained in peripheral blood), 90% of thoracic duct lymphocytes, 30–40% of lymph node cells, and 20–30% of spleen lymphoid cells. In lymph nodes, T cells occupy deep paracortical areas around B cell germinal centers, and in the spleen, they are located in periarteriolar areas of white pulp (Chap. 62). T cells are the primary effectors of cell-mediated immunity, with subsets of T cells maturing into CD8+ cytotoxic T cells capable of lysis of virus-infected or foreign cells (short-lived effector T cells) and CD4+ T cells capable of T cell help for CD8+ T cell and B cell development. Two populations of long-lived memory T cells are triggered by infections: effector memory and central memory T cells. Effector memory T cells reside in nonlymphoid organs and respond rapidly to repeated pathogenic infections with cytokine production and cytotoxic functions to kill virus-infected cells. Central memory T cells home to lymphoid organs where they replenish long- and short-lived and effector memory T cells as needed. In general, CD4+ T cells are the primary regulatory cells of T and B lymphocyte and monocyte function by the production of cytokines and by direct cell contact (Fig. 342-2). In addition, T cells regulate erythroid cell maturation in bone marrow and, through cell contact (CD40 lig and), have an important role in activation of B cells and induction of Ig isotype switching. Considerable evidence now exists that colonization of the gut by commensal bacteria (the gut microbiome) is responsible for expansion of the peripheral CD4+ T cell compartment in normal children and adults. Human T cells express cell-surface proteins that mark stages of intrathymic T cell maturation or identify specific functional subpopula tions of mature T cells. Many of these molecules mediate or participate in important T cell functions (Table 342-1, Fig. 342-5). The earliest identifiable T cell precursors in bone marrow are CD34+ pro-T cells (i.e., cells in which TCR genes are neither rearranged nor expressed). In the thymus, CD34+ T cell precursors begin cytoplasmic (c) synthesis of components of the CD3 complex of TCR-associated molecules (Fig. 342-5). Within T cell precursors, TCR for antigen gene rearrangement yields two T cell lineages, expressing either TCR-αβ chains or TCR-γδ chains. T cells expressing the TCR-αβ chains consti tute the majority of peripheral T cells in blood, lymph node, and spleen and terminally differentiate into either CD4+ or CD8+ cells. Cells expressing TCR-γδ chains circulate as a minor population in blood; their functions, although not fully understood, have been postulated to be those of immune surveillance at epithelial surfaces and cellular defenses against mycobacterial organisms and other intracellular bacteria through recognition of bacterial lipids. In the thymus, the recognition of self-peptides on thymic epithelial cells, thymic macrophages, and DCs plays an important role in shaping T cell repertoire. As immature cortical thymocytes begin to express surface TCR for antigen, thymocytes with TCRs capable of interacting with self-peptides in the context of self-MHC antigens with low affinity are activated and survive (positive selection). Thymocytes with TCRs that are incapable of binding to self-MHC antigens or bind with high affinity, die of attrition (no selection) or by apoptosis (negative selec tion). Thymocytes that are positively selected undergo maturation into CD4 or CD8 single positive T cells, and then migrate to the thymus medulla where they interact with self-peptide-self-MHC molecules, where they can again undergo selection. The purpose of negative and positive thymocyte selection is to eliminate potential pathogenic autoreactive T cells, and at the same time, select a repertoire of mature T cells capable of recognizing foreign antigens. Mature thymocytes that are positively selected are functional MHC class II -restricted CD4+ T cells (Figure 342-2), or they are CD8+ T cells destined to become CD8+ MHC class I -restricted cytotoxic T cells. MHC class I - or class II -restriction means that T cells recognize antigen peptide fragments only when they are presented in the antigen-recognisite of a class I or class II MHC molecule, respectively (Chap. 343). After thymocyte maturation and selection, CD4 and CD8 thymocytes leave the thymus and migrate to the peripheral immune system. The thymus can continue to be a contributor to the peripheral immune system well into adult life, both normally and when the peripheral T cell pool is damaged, such as occurs in AIDS and cancer chemotherapy. MOLECULAR BASIS OF T CELL RECOGNITION OF ANTIGEN The TCR for antigen is a complex of molecules consisting of an antigen-binding heterodimer of either αβ or γδ chains noncovalently linked with five CD3 subunits (γ, δ, ε, ζ, and η) (Fig. 342-6). The CD3 ζ chains are either CHAPTER 342 Introduction to the Immune System disulfide-linked homodimers (CD3-ζ2 ) or disulfide-linked heterodi mers composed of one ζ chain and one η chain. TCR-αβ or TCR-γδ mol ecules must be associated with CD3 molecules to be inserted into the T cell-surface membrane, TCRα being paired with TCR-β and TCR-γ being paired with TCR-δ. Molecules of the CD3 complex mediate transduction of T cell activation signals via TCRs, whereas TCR-α and β or γ and δ molecules combine to form the TCR antigen-binding site. The α, β, γ, and δ TCR for antigen molecules have amino acid sequence homology and structural similarities to immunoglobulin heavy and light chains and are members of the immunoglobulin gene superfamily of molecules. The genes encoding TCR molecules are encoded as clusters of gene segments that rearrange during the course of T cell maturation. This creates an efficient and compact mechanism for housing the diversity requirements of antigen receptor molecules. The TCR-α chain is on chromosome 14 and consists of a series of V (variable), J (joining), and C (constant) regions. The TCR-β chain is on chromosome 7 and consists of multiple V, D (diversity), J, and C TCR-β loci. The TCR-γ chain is on chromosome 7, and the TCR-δ chain is in the middle of the TCR-α locus on chromosome 14. Thus, molecules of the TCR for antigen have constant (framework) and variable regions, and the gene segments encoding the α, β, γ, and δ chains of these molecules are recombined and selected in the thymus, culminating in synthesis of the completed molecule. In both T and B cell precursors (see below), DNA rearrangements of antigen receptor genes involve the same enzymes, recombinase activating gene RAG1 and RAG2, both DNA-dependent protein kinases. TCR diversity is created by the different V, D, and J segments that are possible for each receptor chain by the many permutations of V, D, and J segment combinations, by “N-region diversification” due to the addi tion of nucleotides at the junction of rearranged gene segments, and by the pairing of individual chains to form a TCR dimer. As T cells mature in the thymus, the repertoire of antigen-reactive T cells is modified by selection processes that eliminate many autoreactive T cells, enhance the proliferation of cells that function appropriately with self-MHC molecules and antigen, and allow T cells with nonproductive TCR rear rangements to die. TCR-αβ cells do not recognize native protein or carbohydrate anti gens. Instead, T cells recognize only short (~9–13 amino acids) peptide fragments derived from protein antigens taken up or produced in APCs. Foreign antigens may be taken up by endocytosis into acidified intracel lular vesicles or by phagocytosis and degraded into small peptides that associate with MHC class II molecules (exogenous antigen-presentation 2468 APC β α B7-1 LFA-3 PART 11 ITK PtdIns (4,5)P3 Lipid raft CD3 TCR ICAM-1 CD28 Immune-Mediated, Inflammatory, and Rheumatologic Disorders InsP3 Release of Ca2+ Translocation of NFAT to the nucleus RAS LCK GRB2 LAT CD2 LFA-1 ZAP70 SOS DAG PKC RASGRP Activation of downstream effectors such as NFkB, AP1, and NFAT to induce specific gene transcription leading to cell proliferation and differentiation PLCγ GADS HPK1 Cytoskeletal reorganization VAV1 NCK ADAP Integrin activation MAPK activation FIGURE 342-6 Signaling through the T cell receptor. Activation signals are mediated via immunoreceptor tyrosine-based activation (ITAM) sequences in LAT and CD3 chains (blue bars) that bind to enzymes and transduce activation signals to the nucleus via the indicated intracellular activation pathways. Ligation of the T cell receptor (TCR) by MHC complexed with antigen results in sequential activation of LCK and γ-chain-associated protein kinase of 70 kDa (ZAP70). ZAP70 phosphorylates several downstream targets, including LAT (linker for activation of T cells) and SLP76 (SCR homology 2 [SH2] domain-containing leukocyte protein of 76 kDa). SLP76 is recruited to membrane-bound LAT through its constitutive interaction with GADS (GRB2-related adaptor protein). Together, SLP76 and LAT nucleate a multimolecular signaling complex, which induces a host of downstream responses, including calcium ux, mitogen-activated protein kinase (MAPK) activation, integrin activation, and cytoskeletal reorganization. APC, antigen-presenting cell. (Adapted from GA Koretzky et al: Nat Rev Immunol 6:67, 2006; with permission from Macmillan Publishers Ltd. Copyright 2006.) pathway). Other foreign antigens arise endogenously in the cytosol (such as from replicating viruses) and are broken down into small peptides that associate with MHC class I molecules (endogenous anti gen-presenting pathway). Thus, APCs proteolytically degrade foreign proteins and display peptide fragments embedded in the MHC class I or II antigen-recognition site on the MHC molecule surface, where foreign peptide fragments are available to bind to TCR-αβ or TCR-γδ chains of reactive T cells. CD4 molecules act as adhesives and, by direct binding to MHC class II (DR, DQ, or DP) molecules, stabilize the interaction of TCR with peptide antigen (Fig. 342-6). Similarly, CD8 molecules also act as adhesives to stabilize the TCR-antigen interaction by direct CD8 molecule binding to MHC class I (A, B, or C) molecules. Antigens that arise in the cytosol and are processed via the endoge nous antigen-presentation pathway are cleaved into small peptides by a complex of proteases called the proteasome. From the proteasome, antigen peptide fragments are transported from the cytosol into the lumen of the endoplasmic reticulum by a heterodimeric complex termed transporters associated with antigen processing, or TAP proteins. There, MHC class I molecules in the endoplasmic reticulum membrane physically associate with processed cytosolic peptides. Following peptide association with class I molecules, peptide-class I complexes are exported to the Golgi apparatus, and then to the cell surface, for recognition by CD8+ T cells. Antigens taken up from the extracellular space via endocytosis into intracellular acidified vesicles are degraded by vesicle proteases into peptide fragments. Intracellular vesicles containing MHC class II molecules fuse with peptide-containing vesicles, thus allowing peptide fragments to physically bind to MHC class II molecules. Peptide-MHC class II complexes are then transported to the cell surface for recogni tion by CD4+ T cells (Chap. 343). Whereas it is generally agreed that the TCR-αβ receptor recognizes peptide antigens in the context of MHC class I or class II molecules, lipids in the cell wall of intracellular bacteria such as M. tuberculosis can also be presented to a wide variety of T cells, including subsets of TCR-γδ T cells, and a subset of CD8+ TCR-αβ T cells. Importantly, bacterial lipid antigens are not presented in the context of MHC class I or II molecules, but rather are presented in the context of MHC-related CD1 molecules. Some γδ T cells that recognize lipid antigens via CD1 molecules have very restricted TCR usage, do not need antigen prim ing to respond to bacterial lipids, and may actually be a form of innate rather than acquired immunity to intracellular bacteria. Just as foreign antigens are degraded and their peptide fragments presented in the context of MHC class I or class II molecules on APCs, endogenous self-proteins also are degraded, and self-peptide frag ments are presented to T cells in the context of MHC class I or class II molecules on APCs. In peripheral lymphoid organs, there are T cells that are capable of recognizing self-protein fragments but normally are anergic or tolerant, i.e., nonresponsive to self-antigenic stimulation, due to lack of self-antigen upregulating APC co-stimulatory molecules such as B7-1 (CD80) and B7-2 (CD86) (see below). Once engagement of mature T cell TCR by foreign peptide occurs in the context of self-MHC class I or class II molecules, binding of non-antigen-specific adhesion ligand pairs such as CD54-CD11/CD18 and CD58-CD2 stabilizes MHC peptide-TCR binding, and the expres sion of these adhesion molecules is upregulated (Fig. 342-6). Once anti gen ligation of the TCR occurs, the T cell membrane is partitioned into lipid membrane microdomains, or lipid rafts, that coalesce the key signaling molecules TCR/CD3 complex, CD28, CD2, LAT (linker for activation of T cells), intracellular activated (dephosphorylated) src family protein tyrosine kinases (PTKs), and the key CD3ζ-associated protein-70 (ZAP 70) PTK (Fig. 342-6). Importantly, during T cell activation, the CD45 molecule, with protein tyrosine phosphatase activity, is partitioned away from the TCR complex to allow activating phosphorylation events 2469 to occur. The coalescence of signaling molecules of activated T lympho cytes in microdomains has suggested that T cell-APC interactions can be considered immunologic synapses, analogous in function to neuronal synapses. After TCR-MHC binding is stabilized, activation signals are trans mitted through the cell to the nucleus and lead to the expression of gene products important in mediating the wide diversity of T cell functions such as the secretion of IL-2. The TCR does not have intrinsic signaling activity but is linked to a variety of signaling pathways via ITAMs expressed on the various CD3 chains that bind to proteins that mediate signal transduction. Each of the pathways results in the acti vation of particular transcription factors that control the expression of cytokine and cytokine receptor genes. Thus, antigen-MHC binding to the TCR induces the activation of the src family of PTKs, Fyn and Lck (Lck is associated with CD4 or CD8 co-stimulatory molecules); phos phorylation of CD3ζ chain; activation of the related tyrosine kinases ZAP-70 and Syk; and downstream activation of the calcium-dependent calcineurin pathway, the ras pathway, and the protein kinase C path way. Each of these pathways leads to activation of specific families of transcription factors (including NF-AT, fos and jun, and rel/NF-kB) that form heteromultimers capable of inducing expression of IL-2, IL-2 receptor, IL-4, TNF-α, and other T cell mediators. In addition to the signals delivered to the T cell from the TCR com plex and CD4 and CD8, molecules on the T cell, such as CD28 and inducible co-stimulator (ICOS), and molecules on DCs, such as B7-1 (CD80) and B7-2 (CD86), also deliver important co-stimulatory signals that upregulate T cell cytokine production and are essential for T cell activation. If signaling through CD28 or ICOS does not occur, or if CD28 is blocked, the T cell becomes anergic rather than activated (see “Immune Tolerance and Autoimmunity” below). CTLA-4 (CD152) is similar to CD28 in its ability to bind CD80 and CD86. Unlike CD28, CTLA-4 transmits an inhibitory signal to T cells, acting as an off switch. T CELL EXHAUSTION IN VIRAL INFECTIONS AND CANCER In chronic viral infections such as HIV-1, hepatitis C virus, and hepatitis B virus and in chronic malignancies, the persistence of antigen disrupts memory T cell function, resulting in defects in memory T cell responses. This has been defined as T cell exhaustion and is associated with T cell pro grammed cell death protein 1 (PD-1) (CD279) expression. Exhausted T cells have compromised proliferation and lose the ability to produce effector molecules, like IL-2, TNF-α, and IFN-γ. PD-1 downregulates T cell responses and is associated with T cell exhaustion and disease progression. For this reason, inhibition of T cell PD-1 activity to enhance effector T cell function is being explored as a target for immu notherapy in both viral infections and certain malignancies. T CELL SUPERANTIGENS Conventional antigens bind to MHC class I or II molecules in the groove of the αβ heterodimer and bind to T cells via the V regions of the TCR-α and β chains. In contrast, superantigens bind directly to the lateral portion of the TCR-β chain and MHC class II β chain and stimulate T cells based solely on the Vβ gene segment used independent of the D, J, and Vα sequences present. Superantigens are protein molecules capable of activating up to 20% of the peripheral T cell pool, whereas conventional antigens activate <1 in 10,000 T cells. T cell superantigens include staphylococcal enterotoxins and other bacte rial products. Superantigen stimulation of human peripheral T cells occurs in the clinical setting of staphylococcal toxic shock syndrome, leading to massive overproduction of T cell cytokines that leads to hypotension and shock (Chap. 142). B CELLS Mature B cells constitute 10–15% of human peripheral blood lymphocytes, 20–30% of lymph node cells, 50% of splenic lymphocytes, and ~10% of bone marrow lymphocytes. B cells express on their surface intramembrane immunoglobulin (Ig) molecules that function as BCRs for antigen in a complex of Ig-associated α and β signaling molecules with properties similar to those described in T cells (Fig. 342-7). Unlike T cells, which recognize only processed peptide fragments of conven tional antigens embedded in the notches of MHC class I and class II antigens of APCs, B cells are capable of recognizing and proliferating to whole unprocessed native antigens via antigen binding to B cell–surface Ig (sIg) receptors. B cells also express surface receptors for the Fc region of IgG molecules (CD32) as well as receptors for activated complement components (C3d or CD21, C3b or CD35). The primary function of B cells is to produce antibodies. B cells also serve as APCs and are highly efficient at antigen processing. Their antigen-presenting function is enhanced by a variety of cytokines. Mature B cells are derived from bone marrow precursor cells that arise continuously throughout life (Fig. 342-5). B lymphocyte development can be separated into antigen- independent and antigen-dependent phases. Antigen-independent B cell development occurs in primary lymphoid organs and includes all stages of B cell maturation up to the sIg+ mature B cell. Antigen- dependent B cell maturation is driven by the interaction of antigen with the mature B cell sIg, leading to memory B cell induction, Ig class switching, and plasma cell formation. Antigen-dependent stages of B cell maturation occur in secondary lymphoid organs, including lymph node, spleen, and gut Peyer’s patches. In contrast to the T cell repertoire that is generated intrathymically before contact with foreign antigen, the reper toire of B cells expressing diverse antigen-reactive sites is modified by fur ther alteration of Ig genes after stimulation by antigen—a process called somatic hypermutation—that occurs in lymph node germinal centers. During B cell development, diversity of the antigen-binding variable region of Ig is generated by an ordered set of Ig gene rearrangements that are similar to the rearrangements undergone by TCR α, β, γ, and δ genes. For the heavy chain, there is first a rearrangement of D seg ments to J segments, followed by a second rearrangement between a V gene segment and the newly formed D-J sequence; the C segment is aligned to the V-D-J complex to yield a functional Ig heavy chain gene (V-D-J-C). During later stages, a functional κ or γ light chain gene is generated by rearrangement of a V segment to a J segment, ultimately yielding an intact Ig molecule composed of heavy and light chains. The process of Ig gene rearrangement is regulated and results in a single antibody specificity produced by each B cell, with each Ig molecule comprising one type of heavy chain and one type of light chain. Although each B cell contains two copies of Ig light and heavy chain genes, only one gene of each type is productively rearranged and expressed in each B cell, a process termed allelic exclusion. CHAPTER 342 Introduction to the Immune System There are ~300 Vκ genes and 5 Jκ genes, resulting in the pairing of Vκ and Jκ genes to create >1500 different kappa light chain combinations. There are ~70 Vλ genes and 4 Jλ genes for >280 different lambda light chain combinations. The number of distinct light chains that can be generated is increased by somatic mutations within the V and J genes, thus creating large numbers of possible specificities from a limited amount of germline genetic information. As noted above, in heavy chain Ig gene rearrangement, the VH domain is created by the joining of three types of germline genes called VH , DH , and JH , thus allowing for even greater diversity in the variable region of heavy chains than of light chains. The most immature B cell precursors (early pro-B cells) lack cyto plasmic Ig (cIg) and sIg (Fig. 342-5). The large pre-B cell is marked by the acquisition of the surface pre-BCR composed of μ heavy (H) chains and a pre-B light chain, termed V pre-B. V pre-B is a surrogate light chain receptor encoded by the nonrearranged V pre-B and the γ5 light chain locus (the pre-BCR). Pro- and pre-B cells are driven to proliferate and mature by signals from bone marrow stroma—in particular, IL-7. Light chain rearrangement occurs in the small pre-B cell stage such that the full BCR is expressed at the immature B cell stage. Immature B cells have rearranged Ig light chain genes and express sIgM. As immature B cells develop into mature B cells, sIgD is expressed as well as sIgM. At this point, B lineage development in bone marrow is complete, and B cells exit into the peripheral circulation and migrate to secondary lymphoid organs to encounter specific antigens. Random rearrangements of Ig genes occasionally generate self-reactive antibodies, and mechanisms must be in place to correct these mistakes. One such mechanism is BCR editing, whereby auto reactive BCRs are mutated to not react with self-antigens. If receptor editing is unsuccessful in eliminating autoreactive B cells, then autore active B cells undergo negative selection in the bone marrow through induction of apoptosis after BCR engagement of self-antigen. 2470 Heavy chain Light chain Fab region PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders RAS MAPK activation BCR LYN Cytoskeletal reorganization Igα Igβ PtdIns(4,S)P3 SYK b a VAV1 NCK SOS GRB2 BTK PLCγ SLP65 RASGRP InsP3 Release of Ca2+ DAG PKCβ Activation of downstream effectors FIGURE 342-7 B cell receptor (BCR) activation results in the sequential activation of protein tyrosine kinases, which results in the formation of a signaling complex and activation of downstream pathways as shown. Whereas SLP76 is recruited to the membrane through GADS and LAT, the mechanism of SLP65 recruitment is unclear. Studies have indicated two mechanisms: (a) direct binding by the SH2 domain of SLP65 to immunoglobulin (Ig) of the BCR complex or (b) membrane recruitment through a leucine zipper in the amino terminus of SLP65 and an unknown binding partner. ADAP, adhesion- and degranulation-promoting adaptor protein; AP1, activator protein 1; BTK, Bruton’s tyrosine kinase; DAG, diacylglycerol; GRB2, growth factor receptor-bound protein 2; HPK1, hematopoietic progenitor kinase 1; InsP3 , inositol-1,4,5-trisphosphate; ITK, interleukin-2-inducible T cell kinase; NCK, noncatalytic region of tyrosine kinase; NF-B, nuclear factor B; PKC, protein kinase C; PLC, phospholipase C; PtdIns(4,5)P2 , phosphatidylinositol-4,5-bisphosphate; RASGRP, RAS guanyl-releasing protein; SOS, son of sevenless homologue; SYK, spleen tyrosine kinase. (Adapted from GA Koretzky et al: Nat Rev Immunol 6:67, 2006; with permission from Macmillan Publishers Ltd. Copyright 2006.) After leaving the bone marrow, B cells populate peripheral B cell sites, such as lymph node and spleen, and await contact with foreign antigens that react with each B cell’s clonotypic receptor. Antigen driven B cell activation occurs through the BCR, and a process known as somatic hypermutation takes place whereby point mutations in rearranged H- and L-genes give rise to mutant sIg molecules, some of which bind antigen better than the original sIg molecules. Somatic hypermutation, therefore, is a process whereby memory B cells in peripheral lymph organs have the best binding, or the highest-affinity antibodies. This overall process of generating the best antibodies is called affinity maturation of antibody. Lymphocytes that synthesize IgG, IgA, and IgE are derived from sIgM+, sIgD+ mature B cells. Ig class switching occurs in lymph node and other peripheral lymphoid tissue germinal centers. CD40 on B cells and CD40 ligand on T cells constitute a critical co-stimulatory receptor-ligand pair of immune-stimulatory molecules. Pairs of CD40+ B cells and CD40 ligand+ T cells bind and drive B cell Ig class switching via T cell-produced cytokines such as IL-4 and TGF-β. IL-1, -2, -4, -5, and -6 synergize to drive mature B cells to proliferate and differentiate into Ig-secreting cells. Humoral Mediators of Adaptive Immunity: Immunoglobulins Immunoglobulins are the products of differentiated B cells and mediate the humoral arm of the immune response. The primary functions of antibodies are to bind specifically to antigen and bring about the inac tivation or removal of the offending toxin, microbe, parasite, or other foreign substance from the body. The structural basis of Ig molecule function and Ig gene organization has provided insight into the role of antibodies in normal protective immunity, pathologic immune mediated damage by immune complexes, and autoantibody formation against host determinants. All immunoglobulins have the basic structure of two heavy and two light chains (Fig. 342-7). Immunoglobulin isotype (i.e., G, M, A, D, E) is determined by the type of Ig heavy chain present. IgG and IgA isotypes can be divided further into subclasses (G1, G2, G3, G4, and A1, A2) based on specific antigenic determinants on Ig heavy chains. The char acteristics of human immunoglobulins are outlined in Table 342-12. The four chains are covalently linked by disulfide bonds. Each chain is made up of a V region and C regions (also called domains), themselves made up of units of ~110 amino acids. Light chains have one variable (VL ) and one constant (CL ) unit; heavy chains have one variable unit (VH ) and three or four constant (CH ) units, depending on isotype. As the name suggests, the constant, or C, regions of Ig molecules are made up of homologous sequences and share the same primary structure as all other Ig chains of the same isotype and subclass. Constant regions are involved in biologic functions of Ig molecules. The CH 2 domain of IgG and the CH 4 units of IgM are involved with the binding of the C1q portion of C1 during complement activation. The CH region at the car boxy-terminal end of the IgG molecule, the Fc region, binds to surface Fc receptors (CD16, CD32, CD64) of macrophages, DCs, NK cells, B cells, neutrophils, and eosinophils. The Fc of IgA binds to FcαR (CD89), and the Fc of IgE binds to FcεR (CD23). Variable regions (VL and VH ) constitute the antibody-binding (Fab) region of the molecule. Within the VL and VH regions are hypervariable regions (extreme sequence variability) that constitute the antigen- binding site unique to each Ig molecule. The idiotype is defined as the CHAPTER 342 Introduction to the Immune System 2471 TABLE 342-12 Physical, Chemical, and Biologic Properties of Human Immunoglobulins PROPERTY IgG IgA IgM IgD IgE Usual molecular form Monomer Monomer, dimer Pentamer, hexamer Monomer Monomer Other chains None J chain, SC J chain None None Subclasses G1, G2, G3, G4 A1, A2 None None None Heavy chain allotypes Gm (=30) No A1, A2m (2) None None None Molecular mass, kDa 150 160, 400 950, 1150 175 190 Serum level in average adult, mg/mL 9.5–12.5 1.5–2.6 0.7–1.7 0.04 0.0003 Percentage of total serum Ig 75–85 7–15 5–10 0.3 0.019 Serum half-life, days 23 6 5 3 2.5 Synthesis rate, mg/kg per day 33 65 7 0.4 0.016 Antibody valence 2 2, 4 10, 12 2 2 Classical complement activation +(G1, 2?, 3)–++–– Alternate complement activation +(G4) +–+ Binding cells via Fc Macrophages, neutrophils, large granular lymphocytes Lymphocytes Lymphocytes None Mast cells, basophils, B cells Biologic properties Placental transfer, secondary Ab for most antipathogen responses Secretory immunoglobulin Primary Ab responses Marker for mature B cells Allergy, antiparasite responses Source: After L Carayannopoulos, JD Capra, in WE Paul (ed): Fundamental Immunology, 3rd ed. New York, Raven, 1993; with permission. specific region of the Fab portion of the Ig molecule to which antigen binds. Antibodies against the idiotype portion of an antibody molecule are called anti-idiotype antibodies. The formation of such antibodies in vivo during a normal B cell antibody response may generate a negative (or “off”) signal to B cells to terminate antibody production. IgG constitutes ~75–85% of total serum immunoglobulin. The four IgG subclasses are numbered in order of their level in serum, IgG1 being found in greatest amounts and IgG4 the least. IgG subclasses have clinical relevance in their varying ability to bind macrophage and neutrophil Fc receptors and to activate complement (Table 342-12). Moreover, selective deficiencies of certain IgG subclasses give rise to clinical syndromes in which the patient is inordinately susceptible to bacterial infections. IgG antibodies are frequently the predominant antibody made after rechallenge of the host with antigen (secondary antibody response). IgM antibodies normally circulate as a 950-kDa pentamer with 160-kDa bivalent monomers joined by a molecule called the J chain, a 15-kDa nonimmunoglobulin molecule that also effects polymerization of IgA molecules. IgM is the first immunoglobulin to appear in the immune response (primary antibody response) and is the initial type of antibody made by neonates. Membrane IgM in the monomeric form also functions as a major antigen receptor on the surface of mature B cells (Table 342-12). IgM is an important component of immune com plexes in autoimmune diseases. For example, IgM antibodies against IgG molecules (rheumatoid factors) are present in high titers in rheu matoid arthritis, other collagen diseases, and some infectious diseases (subacute bacterial endocarditis). IgA constitutes only 7–15% of total serum immunoglobulin but is the predominant class of immunoglobulin in secretions. IgA in secretions (tears, saliva, nasal secretions, gastrointestinal tract fluid, and human milk) is in the form of secretory IgA (sIgA), a polymer consisting of two IgA monomers, a joining molecule, again termed the J chain, and a glycoprotein called the secretory protein. Of the two IgA subclasses, IgA1 is primarily found in serum, whereas IgA2 is more prevalent in secretions. IgA fixes complement via the alternative complement path way and has potent antiviral activity in humans by prevention of virus binding to respiratory and gastrointestinal epithelial cells. IgD is found in minute quantities in serum and, together with IgM, is a major receptor for antigen on the naïve B cell surface. IgE, which is present in serum in very low concentrations, is the major class of immu noglobulin involved in arming mast cells and basophils by binding to these cells via the Fc region. Antigen cross-linking of IgE molecules on basophil and mast cell surfaces results in release of mediators of the immediate hypersensitivity (allergic) response (Table 342-12). ■CELLULAR INTERACTIONS IN REGULATION OF NORMAL IMMUNE RESPONSES The net result of activation of the humoral (B cell) and cellular (T cell) arms of the adaptive immune system by foreign antigen is the elimi nation of antigen directly by specific effector T cells or in concert with specific antibody. Figure 342-2 is a simplified schematic diagram of the T and B cell responses indicating some of these cellular interactions. The expression of adaptive immune cell function is the result of a complex series of immunoregulatory events that occur in phases. Both T and B lymphocytes mediate immune functions, and each of these cell types, when given appropriate signals, passes through stages, from activation and induction through proliferation, differentiation, and ultimately effector functions. The effector function expressed may be at the end point of a response, such as secretion of antibody by a differentiated plasma cell, or it might serve a regulatory function that modulates other functions, such as is seen with CD4+ and CD8+ T lym phocytes that modulate both differentiation of B cells and activation of CD8+ cytotoxic T cells. CD4 helper T cells can be subdivided on the basis of cytokines pro duced (Fig. 342-2). Activated TH 1-type helper T cells secrete IL-2, IFN-γ, IL-3, TNF-a, GM-CSF, and TNF-β, whereas activated TH 2-type helper T cells secrete IL-3, -4, -5, -6, -10, and -13. TH 1 CD4+ T cells, through elaboration of IFN-γ, have a central role in mediating intracellular killing by a variety of pathogens. TH 1 CD4+ T cells also provide T cell help for generation of cytotoxic T cells and some types of opsonizing antibody, and they generally respond to antigens that lead to delayed hypersensitivity types of immune responses for many intracellular viruses and bacteria (such as HIV or M. tuberculosis). In contrast, TH 2 cells have a primary role in regulatory humoral immunity and isotype switching. TH 2 cells, through production of IL-4 and IL-10, have a reg ulatory role in limiting proinflammatory responses mediated by TH 1 cells (Fig. 342-2). In addition, TH 2 CD4+ T cells provide help to B cells for specific Ig production and respond to antigens that require high antibody levels for foreign antigen elimination (extracellular encap sulated bacteria such as Streptococcus pneumoniae and certain parasite infections). Additional subsets of the CD4 TH cells have been described, one of which is termed TH 17 that secrete cytokines IL-17, -22, and -26. TH 17 cells have been shown to play a role in autoimmune inflamma tory disorders in addition to defense against extracellular bacteria and fungi, particularly at mucosal surfaces. TH 9 cells are defined by their secretion of IL-9 and have been shown to play a role in atopic disease, inflammatory bowel disease, and in anti-tumor immunity. Moreover, the Tfh subset of helper T cells is crucial for providing the necessary signals to B cells in germinal centers to undergo affinity maturation. 2472 In summary, the type of T cell response generated in an immune response is determined by the microbe PAMPs presented to the DCs, the TLRs on the DCs that become activated, the types of DCs that are activated, and the cytokines that are produced (Table 342-4). Com PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders monly, myeloid DCs produce IL-12 and activate TH 1 T cell responses that result in IFN-γ and cytotoxic T cell induction, and plasmacytoid DCs produce IFN-α and lead to TH 2 responses that result in IL-4 pro duction and enhanced antibody responses. As shown in Fig. 342-2, upon activation by DCs, T cell subsets that produce IL-2, IL-3, IFN-γ, and/or IL-4, -5, -6, -10, and -13 are generated and exert positive and negative influences on effector T and B cells. For B cells, trophic effects are mediated by a variety of cytokines, par ticularly T cell–derived IL-3, -4, -5, and -6, that act at sequential stages of B cell maturation, resulting in B cell proliferation, differentiation, and ultimately antibody secretion. For cytotoxic T cells, trophic factors include inducer T cell secretion of IL-2, IFN-γ, and IL-12. Important types of immunomodulatory T cells that control immune responses are CD4+ and CD8+ T regulatory cells. These cells express the α chain of the IL-2 receptor (CD25), produce IL-10, and suppress both T and B cell responses. T regulatory cells are induced by immature DCs and play key roles in maintaining tolerance to self-antigens. Loss of T regulatory cells is the cause of organ-specific autoimmune disease in mice such as autoimmune thyroiditis, adrenalitis, and oophoritis (see “Immune Tolerance and Autoimmunity” below). T regulatory cells also play key roles in controlling the magnitude and duration of immune responses to microbes. Normally, after the initial immune response to a microbe has eliminated the invader, T regulatory cells are activated to suppress the antimicrobe response and prevent host injury. Some microbes have adapted to induce T regulatory cell activation at the site of infection to promote parasite infection and survival. In Leishmania infection, the parasite induces T regulatory cell accumulation at skin infection sites that dampens anti-Leishmania T cell responses and pre vents parasite elimination. Although B cells recognize native antigen via B cell–surface Ig receptors, B cells require T cell help to produce high-affinity antibody of multiple isotypes that are the most effective in eliminating foreign antigen. T cell–B cell interactions that lead to high-affinity antibody production require (1) processing of native anti gen by B cells and expression of peptide fragments on the B cell surface for presentation to TH cells, (2) the ligation of B cells by both the TCR complex and the CD40 ligand, (3) induction of the process termed anti body isotype switching in antigen-specific B cell clones, and (4) induction of the process of affinity maturation of antibody in the germinal centers of B cell follicles of lymph node and spleen. Naïve B cells express cell-surface IgD and IgM, and initial contact of naïve B cells with antigen is via binding of native antigen to B cell surface IgM. T cell cytokines, released following TH 2 cell contact with B cells or by a “bystander” effect, induce changes in Ig gene conformation that promote recombination of Ig genes. These events then result in the switching of expression of heavy chain exons in a triggered B cell, leading to the secretion of IgG, IgA, or, in some cases, IgE antibody with the same V region antigen specificity as the original IgM antibody, for response to a wide variety of extracellular bacteria, protozoa, and helminths. CD40 ligand expression by activated T cells is critical for induction of B cell antibody isotype switching and for B cell respon siveness to cytokines. Patients with mutations in T cell CD40 ligand have B cells that are unable to undergo isotype switching, resulting in lack of memory B cell generation and the immunodeficiency syndrome of X-linked hyper-IgM syndrome (Chap. 344). ■IMMUNE TOLERANCE AND AUTOIMMUNITY Immune tolerance is defined as the absence of activation of pathogenic autoreactivity to self-antigens. Autoimmune diseases are syndromes caused by the activation of T or B cells or both, with no evidence of other causes such as infections or malignancies (Chap. 348). Immune tolerance and autoimmunity are present normally in health; when abnormal, they represent extremes from the normal state. For exam ple, low levels of autoreactivity of T and B cells with self-antigens in the periphery are critical to T and B cell survival. Similarly, low levels of autoreactivity and thymocyte recognition of self-antigens in the thymus are the mechanisms whereby normal T cells are posi tively selected to survive and leave the thymus to respond to foreign microbes in the periphery and T cells highly reactive to self-antigens are negatively selected and die to prevent overly self-reactive T cells from migrating to the periphery (central tolerance). However, not all self-antigens are expressed in the thymus to delete highly self-reactive T cells, and there are mechanisms for induction of tolerance in periph eral T cells as well. Unlike the presentation of microbial antigens by mature DCs, the presentation of self-antigens by immature DCs neither activates nor matures the DCs to express high levels of co-stimulatory molecules such as B7-1 (CD80) or B7-2 (CD86). When peripheral T cells are stimulated by DCs expressing self-antigens in the context of HLA molecules, sufficient stimulation of T cells occurs to keep them alive, but otherwise they remain anergic, or nonresponsive, until T cells contact a DC with high levels of co-stimulatory molecules expressing microbial antigens and become activated to respond to the microbe. If B cells have high self-reactive BCRs, they normally undergo either dele tion in the bone marrow or receptor editing to express a less autoreac tive receptor. Although many autoimmune diseases are characterized by abnormal or pathogenic autoantibody production (Table 342-13), most autoimmune diseases are caused by a combination of excess T and B cell reactivity. Multiple factors contribute to the genesis of autoimmune disease syndromes, including genetic susceptibility (HLAB27 with ankylosing spondylitis) (Table 342-13), environmental immune stimulants such as drugs (e.g., procainamide and phenytoin [Dilantin] with drug- induced systemic lupus erythematosus), infectious agent triggers (such as Epstein-Barr virus and autoantibody production against red blood cells and platelets), and loss of T regulatory cells (leading to thyroiditis, adrenalitis, and oophoritis). Immunity at Mucosal Surfaces Mucosa covering the respi ratory, digestive, and urogenital tracts; the eye conjunctiva; the inner ear; and the ducts of all exocrine glands contain cells of the innate and adaptive mucosal immune system that protect these surfaces against pathogens. In the healthy adult, mucosa-associated lymphoid tissue (MALT) contains 80% of all immune cells within the body and consti tutes the largest mammalian lymphoid organ system. MALT has three main functions: (1) to protect the mucous membranes from invasive pathogens; (2) to prevent uptake of foreign antigens from food, commensal organisms, and airborne pathogens and particulate matter; and (3) to prevent pathologic immune responses from foreign antigens if they do cross the mucosal barriers of the body (Fig. 342-8). MALT is a compartmentalized system of immune cells that functions independently from systemic immune organs. Whereas the systemic immune organs are essentially sterile under normal conditions and respond vigorously to pathogens, MALT immune cells are continu ously bathed in foreign proteins and commensal bacteria, and they must select those pathogenic antigens that must be eliminated. MALT contains anatomically defined foci of immune cells in the intestine, tonsil, appendix, and peribronchial areas that are inductive sites for mucosal immune responses. From these sites, immune T and B cells migrate to effector sites in mucosal parenchyma and exocrine glands where mucosal immune cells eliminate pathogen-infected cells. In addition to mucosal immune responses, all mucosal sites have strong mechanical and chemical barriers and cleansing functions to repel pathogens. Key components of MALT include specialized epithelial cells called “membrane” or “M” cells that take up antigens and deliver them to DCs or other APCs. Effector cells in MALT include B cells producing antipathogen neutralizing antibodies of secretory IgA as well as IgG isotype, T cells producing similar cytokines as in systemic immune system response, and T helper and cytotoxic T cells that respond to pathogen-infected cells. Secretory IgA is produced in amounts of >50 mg/kg of body weight per 24 h and functions to inhibit bacterial adhesion, inhibit macromol ecule absorption in the gut, neutralize viruses, and enhance antigen elimination in tissue through binding to IgA and receptor-mediated transport of immune complexes through epithelial cells. CHAPTER 342 Introduction to the Immune System 2473 (Continued) AUTOANTIGEN AUTOIMMUNE DISEASES Cell- or Organ-Specific Autoimmunity Acetylcholine receptor Myasthenia gravis Actin Chronic active hepatitis, primary biliary cirrhosis Adenine nucleotide translator (ANT) Dilated cardiomyopathy, myocarditis β-Adrenoreceptor Dilated cardiomyopathy Aromatic L-amino acid decarboxylase Autoimmune polyendocrine syndrome type 1 (APS-1) Asialoglycoprotein receptor Autoimmune hepatitis Bactericidal/permeability-increasing protein (Bpi) Cystic fibrosis vasculitides Calcium-sensing receptor Acquired hypoparathyroidism Cholesterol side-chain cleavage enzyme (CYP11a) Autoimmune polyglandular syndrome-1 Collagen type IV-α3-chain Goodpasture’s syndrome Cytochrome P450 2D6 (CYP2D6) Autoimmune hepatitis Desmin Crohn’s disease, coronary artery disease Desmoglein 1 Pemphigus foliaceus Desmoglein 3 Pemphigus vulgaris F-actin Autoimmune hepatitis GM gangliosides Guillain-Barré syndrome Glutamate decarboxylase (GAD65) Type 1 diabetes, stiff-person syndrome Glutamate receptor (GLUR) Rasmussen encephalitis H/K ATPase Autoimmune gastritis 17-α-Hydroxylase (CYP17) Autoimmune polyglandular syndrome-1 21-Hydroxylase (CYP21) Addison’s disease IA-2 (ICA512) Type 1 diabetes Insulin Type 1 diabetes, insulin hypoglycemic syndrome (Hirata’s disease) Insulin receptor Type B insulin resistance, acanthosis, systemic lupus erythematosus (SLE) Intrinsic factor type 1 Pernicious anemia Leukocyte function-associated antigen (LFA-1) Treatment-resistant Lyme arthritis Myelin-associated glycoprotein (MAG) Polyneuropathy Myelin-basic protein Multiple sclerosis, demyelinating diseases Myelin oligodendrocyte glycoprotein (MOG) Multiple sclerosis Myosin Rheumatic fever p-80-Collin Atopic dermatitis Pyruvate dehydrogenase complex-E2 (PDC-E2) Primary biliary cirrhosis Sodium iodide symporter (NIS) Graves’ disease, autoimmune hypothyroidism SOX-10 Vitiligo Thyroid and eye muscle shared protein Thyroid-associated ophthalmopathy Thyroglobulin Autoimmune thyroiditis Thyroid peroxidase Autoimmune Hashimoto’s thyroiditis Thyrotropin receptor Graves’ disease Tissue transglutaminase Celiac disease Transcription coactivator p75 Atopic dermatitis Tryptophan hydroxylase Autoimmune polyglandular syndrome-1 Tyrosinase Tyrosine hydroxylase Vitiligo, metastatic melanoma Autoimmune polyglandular syndrome-1 Systemic Autoimmunity ACTH ACTH deficiency Aminoacyl-tRNA histidyl synthetase Myositis, dermatomyositis AUTOANTIGEN AUTOIMMUNE DISEASES Aminoacyl-tRNA synthetase (several) Polymyositis, dermatomyositis Cardiolipin Systemic lupus erythematosus, antiphospholipid syndrome Carbonic anhydrase II Systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis Collagen (multiple types) Rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis Centromere-associated proteins Systemic sclerosis DNA-dependent nucleoside-stimulated ATPase Dermatomyositis Fibrillarin Scleroderma Fibronectin Systemic lupus erythematosus, rheumatoid arthritis, morphea Glucose-6-phosphate isomerase Rheumatoid arthritis β2-Glycoprotein I (B2-GPI) Primary antiphospholipid syndrome Golgin (95, 97, 160, 180) Heat shock protein Sjögren’s syndrome, systemic lupus erythematosus, rheumatoid arthritis Various immune-related disorders Hemidesmosomal protein 180 Bullous pemphigoid, herpes gestationis, cicatricial pemphigoid Histone H2A-H2B-DNA Systemic lupus erythematosus IgE receptor Chronic idiopathic urticaria Keratin Rheumatoid arthritis Ku-DNA-protein kinase Systemic lupus erythematosus Ku-nucleoprotein La phosphoprotein (La 55-B) Connective tissue syndrome Sjögren’s syndrome Myeloperoxidase Necrotizing and crescentic glomerulonephritis (NCGN), systemic vasculitis Proteinase 3 (PR3) Granulomatosis with polyangiitis (Wegener’s), Churg-Strauss syndrome RNA polymerase I–III (RNP) Systemic sclerosis, systemic lupus erythematosus Signal recognition protein (SRP54) Polymyositis Topoisomerase-1 (Scl-70) Scleroderma, Raynaud’s syndrome Tublin Chronic liver disease, visceral leishmaniasis Vimentin Systemic autoimmune disease Plasma Protein and Cytokine Autoimmunity C1 inhibitor Autoimmune C1 deficiency C1q Systemic lupus erythematosus, membrane proliferative glomerulonephritis (MPGN) Cytokines (IL-1α, IL-1β, IL-6, IL-10, LIF) Rheumatoid arthritis, systemic sclerosis, normal subjects Factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, thrombin vWF Prolonged coagulation time Glycoprotein IIb/IIIg and Ib/IX Autoimmune thrombocytopenia purpura IgA Immunodeficiency associated with systemic lupus erythematosus, pernicious anemia, thyroiditis, Sjögren’s syndrome, and chronic active hepatitis Oxidized LDL (OxLDL) Atherosclerosis Cancer and Paraneoplastic Autoimmunity Amphiphysin Neuropathy, small-cell lung cancer Cyclin B1 Hepatocellular carcinoma DNA topoisomerase II Liver cancer Desmoplakin Paraneoplastic pemphigus Gephyrin Paraneoplastic stiff-person syndrome TABLE 342-13Recombinant or Purified Autoantigens Recognized by Autoantibodies Associated with Human Autoimmune Disorders 2474 TABLE 342-13 Recombinant or Purified Autoantigens Recognized by Autoantibodies Associated with Human Autoimmune Disorders (Continued) AUTOANTIGEN AUTOIMMUNE DISEASES Cancer and Paraneoplastic Autoimmunity (Continued) PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders Hu proteins Neuronal nicotinic acetylcholine receptor p53 p62 (IGF-II mRNA-binding protein) Paraneoplastic encephalomyelitis Subacute autonomic neuropathy, cancer Cancer, systemic lupus erythematosus Hepatocellular carcinoma (China) Recoverin AUTOANTIGEN Ri protein βIV spectrin Synaptotagmin Voltage-gated calcium channels Yo protein AUTOIMMUNE DISEASES Cancer-associated retinopathy Source: From A Lernmark et al: J Clin Invest 108:1091, 2001; with permission. Recent studies have demonstrated the importance of commensal gut and other mucosal bacteria to the health of the human immune system. Normal commensal flora induces anti-inflammatory events in the gut and protects epithelial cells from pathogens through TLRs and other PRR signaling. When the gut is depleted of normal commensal flora, the immune system becomes abnormal, with loss of TH 1 T cell func tion. Restoration of the normal gut flora can reestablish the balance in T helper cell ratios characteristic of the normal immune system. Diet also has an impact on the gut microbiome. Altered microbiome composition has been etiologically related to obesity, insulin resistance and diabetes. When the gut barrier is intact, either antigens do not transverse the gut epithelium or, when pathogens are present, a self-limited, protective MALT immune response eliminates the pathogen (Fig. 342-8). However, when the gut barrier breaks down, immune responses to commensal flora antigens can cause inflammatory bowel diseases such as Crohn’s dis ease and, perhaps, ulcerative colitis (Fig. 342-8) (Chap. 319). Uncontrolled MALT immune responses to food antigens, such as gluten, can cause celiac disease (Chap. 319). ■THE CELLULAR AND MOLECULAR CONTROL OF PROGRAMMED CELL DEATH The process of apoptosis (programmed cell death) plays a crucial role in regulating normal immune responses to antigen. In general, a wide vari ety of stimuli trigger one of several apoptotic pathways to eliminate Barrier specialized for antigen uptake FAE transports antigens into Peyer’s patch Intact barrier No antigen in lamina propria Paraneoplastic opsoclonus myoclonus ataxia Lower motor neuron syndrome Lambert-Eaton myasthenic syndrome Lambert-Eaton myasthenic syndrome Paraneoplastic cerebellar degeneration microbe-infected cells, eliminate cells with damaged DNA, or eliminate activated immune cells that are no longer needed (Fig. 342-9). The largest known family of “death receptors” is the TNF receptor (TNF-R) family (TNF-R1, TNF-R2, Fas [CD95], death receptor 3 [DR3], death receptor 4 [DR4; TNF-related apoptosis-including ligand receptor 1, or TRAIL-R1], and death receptor 5 [DR5, TRAIL-R2]); their ligands are all in the TNF-α family. Binding of ligands to these death recep tors leads to a signaling cascade that involves activation of the caspase family of molecules that leads to DNA cleavage and cell death. Two other pathways of programmed cell death involve nuclear p53 in the elimination of cells with abnormal DNA and mitochondrial cytochrome c to induce cell death in damaged cells (Fig. 342-9). A number of human diseases have now been described that result from, or are associated with, mutated apoptosis genes (Table 342-14). These include mutations in the Fas and Fas ligand genes in autoimmune and lymphoprolifera tion syndromes, and multiple associations of mutations in genes in the apoptotic pathway with malignant syndromes. ■MECHANISMS OF IMMUNE-MEDIATED DAMAGE TO MICROBES OR HOST TISSUES Leaky barrier Antigen enters lamina propria T cells die by apoptosis T cell sensitization Emigration Cytokines disrupt epithelium INFγ TNFα Mesenteric lymph node Blood T cell response Extravasation into lamina propria Vicious cycle of chronic inflammation FIGURE 342-8 Increased epithelial permeability may be important in the development of chronic gut T cell mediated inflammation. CD4 T cells activated by gut antigens in Peyer’s patches migrate to the lamina propria (LP). In healthy individuals, these cells die by apoptosis. Increased epithelial permeability may allow suf cient antigen to enter the LP to trigger T cell activation, breaking tolerance mediated by immunosuppressive cytokines and perhaps T regulatory cells. Proinammatory cytokines then further increase epithelial permeability, setting up a vicious cycle of chronic inammation. (From TT MacDonald et al: Science 307:1920, 2005; with permission.) Several responses by the host innate and adaptive immune systems to foreign microbes culminate in rapid and efficient elimination of microbes. In these scenarios, the classic weapons of the adaptive immune system (T cells, B cells) interface with cells (macrophages, DCs, NK cells, neutrophils, eosinophils, basophils) and sol uble products (microbial peptides, pentrax ins, complement and coagulation systems) of the innate immune system (Chaps. 60 and 345). There are five general phases of host defenses: (1) migration of leukocytes to sites of antigen localization; (2) antigen-nonspe cific recognition of pathogens by macro phages and other cells and systems of the innate immune system; (3) specific recog nition of foreign antigens mediated by T and B lymphocytes; (4) amplification of the inflammatory response with recruit ment of specific and nonspecific effector cells by complement components, cytok ines, kinins, arachidonic acid metabolites, and mast cell–basophil products; and (5) macrophage, neutrophil, and lymphocyte participation in destruction of antigen with ultimate removal of antigen particles by phagocytosis (by macrophages or neu trophils) or by direct cytotoxic mechanisms (involving macrophages, neutrophils, DCs, and lymphocytes). Under normal circum stances, orderly progression of host defenses through these phases results in a well- controlled immune and inflammatory response that protects the host from the offending antigen. However, dysfunction of Death-receptor-mediated 2475 (FAS, TNF, TRAIL) Death ligand Death Receptor Mitochondrial-mediated (γ Radiation) Oxygen radicals DNA injury BIM, PUMA, other BH3-only proteins ? BCL-XL-BCL2 FADD Capsase 8 IAPS SMAC/DIABLO BAX c-FLIP tBID BID BCL2-BCL-XL BAK Cytochrome c Caspase 3 Cytochrome c APAF1 SMAC/DIABLO Substrate cleavage Apoptosis Caspase 9 activation IAPS FIGURE 342-9 Pathways of cellular apoptosis. There are two major pathways of apoptosis: the death-receptor pathway, which is mediated by activation of death receptors, and the BCL2 regulated mitochondrial pathway, which is mediated by noxious stimuli that ultimately lead to mitochondrial injury. Ligation of death receptors recruits the adaptor protein FAS-associated death domain (FADD). FADD in turn recruits caspase 8, which ultimately activates caspase 3, the key “executioner” caspase. Cellular FLICE-inhibitory protein (c-FLIP) can either inhibit or potentiate binding of FADD and caspase 8, depending on its concentration. In the intrinsic pathway, proapoptotic BH3 proteins are activated by noxious stimuli, which interact with and inhibit antiapoptotic BCL2 or BCL-XL. Thus, BAX and BAK are free to induce mitochondrial permeabilization with release of cytochrome c, which ultimately results in the activation of caspase 9 through the apoptosome. Caspase 9 then activates caspase 3. SMAC/DIABLO is also released after mitochondrial permeabilization and acts to block the action of inhibitors of apoptosis protein (IAPs), which inhibit caspase activation. There is potential cross-talk between the two pathways, which is mediated by the truncated form of BID (tBID) that is produced by caspase 8–mediated BID cleavage; tBID acts to inhibit the BCL2-BCL-XL pathway and to activate BAX and BAK. There is debate (indicated by the question mark) as to whether proapoptotic BH3 molecules (e.g., BIM and PUMA) act directly on BAX and BAK to induce mitochondrial permeability or whether they act only on BCL2-BCL-XL. APAF1, apoptotic protease-activating factor 1; BH3, BCL homologue; TNF, tumor necrosis factor; TRAIL, TNF-related apoptosis-inducing ligand. (From RS Hotchkiss et al: N Engl J Med 361:1570, 2009; with permission.) any of the host defense systems can damage host tissue and produce clinical disease. Furthermore, for certain pathogens or antigens, the normal immune response itself might contribute substantially to the tissue damage. For example, the immune and inflammatory response in the brain to certain pathogens such as M. tuberculosis may be respon sible for much of the morbidity rate of this disease in that organ system (Chap. 173). In addition, the morbidity rate associated with certain pneumonias such as that caused by Pneumocystis jiroveci may be associ ated more with inflammatory infiltrates than with the tissue-destructive effects of the microorganism itself (Chap. 215). Adhesion molecule expression on lymphocytes and endo thelial cells regulates the retention and subsequent egress of lymphocytes within tissue sites of antigenic stimulation, delaying cell exit from tissue and preventing reentry into the circulating lymphocyte pool (Fig. 342-10). All types of lymphocyte migration begin with lymphocyte attachment to specialized regions of vessels, termed high endothelial venules (HEVs). An important concept is that adhesion molecules do not generally bind their ligand until a conformational change (ligand activation) occurs in the adhesion molecule that allows ligand binding. Induction of a conformation-dependent determinant on an adhesion molecule can be accomplished by cytokines or via ligation of other adhesion molecules on the cell. The first stage of lymphocyte–endothelial cell inter actions, attachment and rolling, occurs when lymphocytes leave the stream of flowing blood cells in a postcapillary venule and roll along venule endothelial cells (Fig. 342-10). Lymphocyte rolling is mediated by the l-selectin mole cule (LECAM-1, LAM-1, CD62L) and slows cell transit time through venules, allowing time for activation of adherent cells. The second stage of lymphocyte–endothelial cell inter actions, firm adhesion with activation-dependent stable arrest, requires stimulation of lymphocytes by chemoattrac tants or by endothelial cell–derived cytokines. Cytokines thought to participate in adherent cell activation include members of the IL-8 family, platelet-activation factor, leu CHAPTER 342 Introduction to the Immune System kotriene B4 , and C5a. In addition, HEVs express chemok ines, SLC (CCL21) and ELC (CCL19), which participate in this process. Following activation by chemoattractants, lymphocytes shed l-selectin from the cell surface and upregulate cell CD11b/18 (MAC-1) or CD11a/18 (LFA-1) molecules, resulting in firm attachment of lymphocytes to HEVs. Lymphocyte homing to peripheral lymph nodes involves adhesion of l-selectin to glycoprotein HEV lig ands collectively referred to as peripheral node addressin (PNAd), whereas homing of lymphocytes to intestine Peyer’s patches primarily involves adhesion of the a4β7 integrin to mucosal addressin cell adhesion mole cule-1 (MAdCAM-1) on the Peyer’s patch HEVs. How ever, for migration to mucosal Peyer’s patch lymphoid aggregates, naïve lymphocytes primarily use l-selectin, whereas memory lymphocytes use a4β7 integrin. a4β1 integrin (CD49d/CD29, VLA-4)–VCAM-1 interactions are important in the initial interaction of memory lympho cytes with HEVs of multiple organs in sites of inflamma tion (Table 342-15). The third stage of leukocyte emigration in HEVs is sticking and arrest. Sticking of the lymphocyte to endothelial cells and arrest at the site of sticking are mediated predom inantly by ligation of a1β2 integrin LFA-1 to the integrin ligand ICAM-1 on HEVs. Whereas the first three stages of lymphocyte attachment to HEVs take only a few seconds, the fourth stage of lymphocyte emigra tion, transendothelial migration, takes ~10 min. Although the molecular mechanisms that control lymphocyte transendothelial migration are not fully characterized, the HEV CD44 molecule and molecules of the HEV glycocalyx (extracellular matrix) are thought to play important regulatory roles in this process (Fig. 342-10). Finally, expression of matrix metallo proteases capable of digesting the subendothelial basement membrane, rich in nonfibrillar collagen, appears to be required for the penetration of lymphoid cells into the extravascular sites. Molecular Basis of Lymphocyte–Endothelial Cell Interactions The control of lymphocyte circulatory patterns between the bloodstream and peripheral lymphoid organs operates at the level of lymphocyte–endothelial cell interactions to control the specificity of lymphocyte subset entry into organs. Similarly, lymphocyte–endothelial cell interactions regulate the entry of lymphocytes into inflamed tissue. Abnormal induction of HEV formation and use of the molecules discussed above have been implicated in the induction and mainte nance of inflammation in a number of chronic inflammatory diseases. In animal models of type 1 diabetes mellitus, MAdCAM-1 and Gly CAM-1 have been shown to be highly expressed on HEVs in inflamed pancreatic islets, and treatment of these animals with inhibitors of PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2476 TABLE 342-14 Immune System Molecule Defects in Animals or Humans That Cause Autoimmune or Malignant Syndromes PROTEIN DEFECT DISEASE OR SYNDROME OBSERVATION IN ANIMAL MODELS OR HUMANS Cytokines and Signaling Proteins Tumor necrosis factor (TNF) α Overexpression Inflammatory bowel disease (IBD), arthritis, vasculitis Mice TNF-α Underexpression Systemic lupus erythematosus (SLE) Mice Interleukin (IL)-1-receptor antagonist Underexpression Arthritis Mice IL-2 Overexpression IBD Mice IL-7 Overexpression IBD Mice IL-10 Overexpression IBD Mice IL-2 receptor Overexpression IBD Mice IL-10 receptor Overexpression IBD Mice IL-3 Overexpression Demyelinating syndrome Mice Interferon-δ Overexpression in skin SLE Mice STAT-3 Underexpression IBD Mice STAT-4 Overexpression IBD Mice Transforming growth factor (TGF) β Underexpression Systemic wasting syndrome and IBD Mice TGF-β receptor in T cells Underexpression SLE Mice Programmed death (CD279, PD-1) Underexpression SLE-like syndrome Mice Cytotoxic T lymphocyte, antigen-4 (CTLA-4) Underexpression Systemic lymphoproliferative disease Mice IL-10 Underexpression IBD (mouse), type 1 diabetes, thyroid disease, primary (human) Mice and humans Major Histocompatibility Locus Moleculesa HLA-B27 Allele expression or overexpression Inflammatory bowel disease Rats and humans Complement deficiency of C1, 2, 3 or 4 Underexpression Humans LIGHT (TNF superfamily 14) Overexpression Systemic lymphoproliferative (mouse) and autoimmunity Mice HLA class II DQB10301, DQB10302 Allele expression Juvenile-onset diabetes Humans HLA class II DQB10401, DQB10402 Allele expression Rheumatoid arthritis Humans HLA class I B27 Allele expression Ankylosing spondylitis, IBD Rats and humans Apoptosis Proteins TNF receptor 1 (TNF-R1) Underexpression Familial periodic fever syndrome Humans Fas (CD95; Apo-1) Underexpression Autoimmune lymphoproliferative syndrome type 1 (ALPS 1); malignant lymphoma; bladder cancer Humans Fas ligand Underexpression SLE (only one case identified) Humans Perforin Underexpression Familial hemophagocytic lymphohistiocytosis (FHL) Humans Caspase 10 Underexpression Autoimmune lymphoproliferative syndrome type II (ALPS II) Humans bcl-10 Underexpression Non-Hodgkin’s lymphoma Humans P53 Underexpression Various malignant neoplasms Humans Bax Underexpression Colon cancer; hematopoietic malignancies Humans bcl-2 Underexpression Non-Hodgkin’s lymphoma Humans c-IAP2 Underexpression Low-grade MALT lymphoma Humans NAIP1 Underexpression Spinal muscular atrophy Humans aMany autoimmune diseases are associated with a myriad of major histocompatibility complex gene allele (HLA) types. They are presented here as examples. Abbreviation: MALT, mucosa-associated lymphoid tissue. Source: Adapted from L Mullauer: Mutat Res 488:211, 2001; and A Davidson, B Diamond: N Engl J Med 345:340, 2001. l-selectin and a4 integrin function blocked the development of type 1 diabetes mellitus (Chap. 396). A similar role for abnormal induction of the adhesion molecules of lymphocyte emigration has been suggested in rheumatoid arthritis (Chap. 351), Hashimoto’s thyroiditis (Chap. 375), Graves’ disease (Chap. 375), multiple sclerosis (Chap. 436), Crohn’s disease (Chap. 319), and ulcerative colitis (Chap. 319). Immune-Complex Formation Clearance of antigen by immune-complex formation between antigen, complement, and antibody is a highly effective mechanism of host defense. However, depending on the level of immune complexes formed and their physicochemical prop erties, immune complexes may or may not result in host and foreign cell damage. After antigen exposure, certain types of soluble antigen-antibody complexes freely circulate and, if not cleared by the reticuloendothelial system, can be deposited in blood vessel walls and in other tissues such as renal glomeruli and cause vasculitis or glomerulonephritis syndromes (Chaps. 308 and 356). Deficiencies of early complement components are associated with inefficient clearance of immune complexes and immune complex mediated tissue damage in autoimmune syndromes, whereas deficiencies of the later complement components are associated with susceptibility to recurrent Neisseria infections (Table 342-16). Immediate-Type Hypersensitivity Helper T cells that drive antiallergen IgE responses are usually TH 2-type inducer T cells that secrete IL-4, IL-5, IL-6, and IL-10. Mast cells and basophils have high-affinity receptors for the Fc portion of IgE (FcRI), and cell-bound antiallergen IgE effectively “arms” basophils and mast cells. Mediator release is trig gered by antigen (allergen) interaction with Fc receptor-bound IgE, and the mediators released are responsible for the pathophysiologic changes of allergic diseases (Table 342-11). Mediators released from mast cells and Blood vessel lumen 2477 1. Tethering and rolling 2. Chemokine signal 3. Arrest 4. Polarization and diapedesis 5. Junctional rearrangement 6. Proteolysis Basement membrane Lymph vessel DC Damaged or inflamed tissue 8. DC migration to draining LN Selectin s ialomucin Resting Collagen actve integrins Inflammatory chemoattractants ICAM-1 or VCAM-1 GPCR Cytokine stimulated parenchymal cell 7. Interstitial migration ECM with GAG CCL19 CCL21 CCR7 FIGURE 342-10 Key migration steps of immune cells at sites of inflammation. Inammation due to tissue damage or infection induces the release of cytokines (not shown) and inammatory chemoattractants (red arrowheads) from distressed stromal cells and “professional” sentinels, such as mast cells and macrophages (not shown). The inammatory signals induce upregulation of endothelial selectins and immunoglobulin “superfamily” members, particularly ICAM-1 and/or VCAM-1. Chemoattractants, particularly chemokines, are produced by or translocated across venular endothelial cells (red arrow) and are displayed in the lumen to rolling leukocytes. Those leukocytes that express the appropriate set of traf cking molecules undergo a multistep adhesion cascade (steps 1–3) and then polarize and move by diapedesis across the venular wall (steps 4 and 5). Diapedesis involves transient disassembly of endothelial junctions and penetration through the underlying basement membrane (step 6). Once in the extravascular (interstitial) space, the migrating cell uses different integrins to gain “footholds” on collagen bers and other ECM molecules, such as laminin and bronectin, and on inammation-induced ICAM-1 on the surface of parenchymal cells (step 7). The migrating cell receives guidance cues from distinct sets of chemoattractants, particularly chemokines, which may be immobilized on glycosaminoglycans (GAG) that “decorate” many ECM molecules and stromal cells. Inammatory signals also induce tissue dendritic cells (DCs) to undergo maturation. Once DCs process material from damaged tissues and invading pathogens, they upregulate CCR7, which allows them to enter draining lymph vessels that express the CCR7 ligand CCL21 (and CCL19). In lymph nodes (LNs), these antigen-loaded mature DCs activate naïve T cells and expand pools of effector lymphocytes, which enter the blood and migrate back to the site of inammation. T cells in tissue also use this CCR7-dependent route to migrate from peripheral sites to draining lymph nodes through afferent lymphatics. (Adapted from AD Luster et al: Nat Immunol 6:1182, 2005; with permission from Macmillan Publishers Ltd. Copyright 2005.) basophils can be divided into three broad functional types: (1) those that increase vascular permeability and contract smooth muscle (histamine, platelet-activating factor, SRS-A, BK-A), (2) those that are chemotactic for or activate other inflammatory cells (ECF-A, NCF, leukotriene B4 ), and (3) those that modulate the release of other mediators (BK-A, plate let-activating factor) (Chap. 345). Cytotoxic Reactions of Antibody In this type of immunologic injury, complement-fixing (C1-binding) antibodies against normal or foreign cells or tissues (IgM, IgG1, IgG2, IgG3) bind complement via the classic pathway and initiate a sequence of events similar to that initiated by immune-complex deposition, resulting in cell lysis or tissue injury. Examples of antibody-mediated cytotoxic reactions include red cell lysis in transfusion reactions, Goodpasture’s syndrome with anti–glomerular basement membrane antibody formation, and pemphigus vulgaris with antiepidermal antibodies inducing blistering skin disease. Delayed-Type Hypersensitivity Reactions Inflammatory reactions initiated by mononuclear leukocytes and not by antibody alone have been termed delayed-type hypersensitivity reactions. The term delayed has been used to contrast a secondary cellular response that appears 48–72 h after antigen exposure with an immediate hypersen sitivity response generally seen within 12 h of antigen challenge and initiated by basophil mediator release or preformed antibody. For example, in an individual previously infected with M. tuberculosis organisms, intradermal placement of tuberculin purified protein deriv ative as a skin test challenge results in an indurated area of skin at 48–72 h, indicating previous exposure to tuberculosis. The cellular events that result in classic delayed-type hypersensi tivity responses are centered on T cells (predominantly, although not exclusively, IFN-γ, IL-2, and TNF-α-secreting TH 1-type helper T cells) and macrophages. Recently, NK cells have been suggested to play a major role in the form of delayed hypersensitivity that occurs following skin contact with immunogens. First, local immune and inflammatory responses at the site of foreign antigen upregulate endothelial cell adhesion molecule expression, promoting the accumulation of lym phocytes at the tissue site. In the general scheme outlined in Fig. 342-2, antigen is processed by DCs and presented to small numbers of CD4+ T cells expressing a TCR specific for the antigen. IL-12 produced by APCs induces T cells to produce IFN-γ (TH 1 response). Macrophages frequently undergo epithelioid cell transformation and fuse to form CHAPTER 342 Introduction to the Immune System PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders 2478 TABLE 342-16 Complement Deficiencies and Associated Diseases COMPONENT ASSOCIATED DISEASES Classic Pathway Clq, Clr, Cls, C4 Immune-complex syndromes,a pyogenic infections C2 Immune-complex syndromes,a few with pyogenic infections C1 inhibitor Rare immune-complex disease, few with pyogenic infections C3 and Alternative Pathway C3 C3 Immune-complex syndromes,a pyogenic infections D Pyogenic infections Properdin Neisseria infections I Pyogenic infections H Hemolytic-uremic syndrome Membrane Attack Complex C5, C6, C7, C8 Recurrent Neisseria infections, immune-complex disease C9 Rare Neisseria infections aImmune-complex syndromes include systemic lupus erythematosus (SLE) and SLE-like syndromes, glomerulonephritis, and vasculitis syndromes. Source: After JA Schifferli, DK Peters: Lancet 322:957, 1983. Copyright 1983, with permission from Elsevier. TABLE 342-15 Trafficking Molecules Involved In Inflammatory Disease Processes PROPOSED LEUKOCYTE RECEPTORS FOR ENDOTHELIAL TRAFFIC SIGNALS DISEASE KEY EFFECTOR CELL L-SELECTIN, LIGAND GPCR INTEGRINa Acute Inflammation Myocardial infarction Neutrophil PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1 Stroke Neutrophil L-Selectin, PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1 Ischemia-reperfusion Neutrophil PSGL-1 CXCR1, CXCR2, PAFR, BLT1 LFA-1, Mac-1 TH 1 Inflammation Atherosclerosis Monocyte PSGL-1 CCR1, CCR2, BLT1, CXCR2, CX3CR1 VLA-4 TH 1 PSGL-1 CXCR3, CCR5 VLA-4 Multiple sclerosis TH 1 PSGL-1 (?) CXCR3, CXCR6 VLA-4, LFA-1 Monocyte PSGL-1 (?) CCR2, CCR1 VLA-4, LFA-1 Rheumatoid arthritis Monocyte PSGL-1 CCR1, CCR2 VLA-1, VLA-2, VLA-4, LFA-1 TH 1 PSGL-1 CXCR3, CXCR6 VLA-1, VLA-2, VLA-4, LFA-1 Neutrophil L-Selectin, PSGL-1 CXCR2, BLT1 LFA-1b Psoriasis Skin-homing TH 1 CLA CCR4, CCR10, CXCR3 VLA-4c, LFA-1 Crohn’s disease Gut-homing TH 1 PSGL-1 CCR9, CXCR3 α4, β7, LFA-1 Type 1 diabetes TH 1 PSGL-1 (?) CCR4, CCR5 VLA-4, LFA-1 CD8 L-Selectin (?), PSGL-1 (?) CXCR3 VLA-4, LFA-1 Allograft rejection CD8 PSGL-1 CXCR3, CX3CR1, BLT1 VLA-4, LFA-1 B cell L-Selectin, PSGL-1 CXCR5, CXCR4 VLA-4, LFA-1 Hepatitis CD8 PSGL-1 CXCR3, CCR5, CXCR6 VLA-4 Lupus TH 1 None CXCR6 VLA-4d Plasmacytoid DC L-Selectin, CLA CCR7, CXCR3, ChemR23 LFA-1, Mac-1 B cell CLA (?) CXCR5, CXCR4 LFA-1 TH 2 Inflammation Asthma TH 2 PSGL-1 CCR4, CCR8, BLT1 LFA-1 Eosinophil PSGL-1 CCR3, PAFR, BLT1 VLA-4, LFA-1 Mast cells PSGL-1 CCR2, CCR3, BLT1 VLA-4, LFA-1 Atopic dermatitis Skin-homing TH 2 CLA CCR4, CCR10 VLA-4, LFA-1 aVarious β1 integrins have been linked in different ways in basal lamina and interstitial migration of distinct cell types and inflammatory settings. bIn some settings, Mac-1 has been linked to transmigration. cCD44 can act in concert with VLA-4 in particular models of leukocyte arrest. dTH 2 cells require VAP-1 to traffic to inflamed liver. Source: From AD Luster et al: Nat Immunol 6:1182, 2005; with permission from Macmillan Publishers Ltd. Copyright 2005. multinucleated giant cells in response to IFN-γ. This type of mononu clear cell infiltrate is termed granulomatous inflammation. Examples of diseases in which delayed-type hypersensitivity plays a major role are fungal infections (histoplasmosis; Chap. 207), mycobacterial infections (tuberculosis, leprosy; Chaps. 173 and 174), chlamydial infections (lym phogranuloma venereum; Chap. 184), helminth infections (schistosomiasis; Chap. 229), reactions to toxins (berylliosis; Chap. 283), and hypersen sitivity reactions to organic dusts (hypersensitivity pneumonitis; Chap. 282). In addition, delayed-type hypersensitivity responses play impor tant roles in tissue damage in autoimmune diseases such as rheuma toid arthritis, temporal arteritis, and granulomatosis with polyangiitis (Wegener’s) (Chaps. 351 and 356). Autophagy Autophagy is a process that involves a lysosomal deg radation pathway mechanism of cells to dispose of intracellular debris and damaged organelles. Autophagy by cells of the innate immune system is used to control intracellular infectious agents such as Myco bacterium tuberculosis, in part by initiation of phagosome maturation and enhancing MHC class II antigen presentation to CD4 T cells. ■CLINICAL EVALUATION OF IMMUNE FUNCTION Clinical assessment of immunity requires investigation of the four major components of the immune system that participate in host defense and in the pathogenesis of autoimmune diseases: (1) humoral immunity (B cells); (2) cell-mediated immunity (T cells, monocytes); (3) phagocytic cells of the reticuloendothelial system (macrophages), as well as polymorphonuclear leukocytes; and (4) complement. Clin ical problems that require an evaluation of immunity include chronic infections, recurrent infections, unusual infecting agents, and certain autoimmune syndromes. The type of clinical syndrome under eval uation can provide information regarding possible immune defects (Chap. 344). Defects in cellular immunity generally result in viral, mycobacterial, and fungal infections. An extreme example of deficiency in cellular immunity is AIDS (Chap. 197). Antibody deficiencies result in recurrent bacterial infections, frequently with organisms such as S. pneumoniae and Haemophilus influenzae (Chap. 344). Disorders of phagocyte function are frequently manifested by recurrent skin infec tions, often due to Staphylococcus aureus (Chap. 60). Finally, deficiencies 2479 of early and late complement components are associated with auto immune phenomena and recurrent Neisseria infections (Table 342-16). For further discussion of useful initial screening tests of immune function, see Chap. 344. ■IMMUNOTHERAPY Many therapies for autoimmune and inflammatory diseases involve the use of nonspecific immune-modulating or immunosuppressive agents such as glucocorticoids or cytotoxic drugs. The goal of devel opment of new treatments for immune-mediated diseases is to design ways to specifically interrupt pathologic immune responses, leaving nonpathologic immune responses intact. Novel ways to interrupt pathologic immune responses that are under investigation include the use of anti-inflammatory cytokines or specific cytokine inhibitors as anti-inflammatory agents, the use of monoclonal antibodies against T or B lymphocytes as therapeutic agents, the use of intravenous Ig for certain infections and immune complex–mediated diseases, the use of specific cytokines to reconstitute components of the immune system, and bone marrow transplantation to replace the pathogenic immune system with a more normal immune system (Chaps. 60, 344, and 197). In particular, the use of a monoclonal antibody to B cells (rituximab, anti-CD20 MAb) is approved in the United States for the treatment of non-Hodgkin’s lymphoma (Chap. 104) and, in combination with methotrexate, for treatment of adult patients with severe rheumatoid arthritis resistant to TNF-α inhibitors (Chap. 351). CTLA-4 inhibitors such as Ipilimumab and Tremelimumab and anti-PD-1 antibodies such as Nivolumab have been shown to reverse CD8 T cell exhaustion in melanoma and other solid tumors and induce immune cell control of tumor growth. CTLA4 and PD-1 inhibitors are currently being studied in HCV or HIV-1 infection to reverse anti-viral CD8 T cell dysfunction and promote the reduction of virus infected cells. A new technique that engineers autologous T cells to express antibody receptors that target leukemic cells, termed T cells with chimeric antigen receptors (T CARs), is currently showing promising results in clinical trials for the treatment of certain types of leukemias and lymphomas. Cell-based therapies have been studied for many years, including ex vivo activation of NK cells for reinfusion into patients with malignan cies, and DC therapy of ex vivo priming of DCs for enhanced presenta tion of cancer antigens, with reinfusion of primed DCs into the patient. One such strategy for DC therapy has been approved by the FDA for treatment of advanced prostate cancer. Cytokines and Cytokine Inhibitors Several TNF inhibitors are used as biological therapies in the treatment of rheumatoid arthri tis; these include monoclonal antibodies, TNF-R Fc fusion proteins, and Fab fragments. Use of anti-TNF-α antibody therapies such as adalimumab, infliximab, and golimumab has resulted in clinical improvement in patients with these diseases and has opened the way for targeting TNF-α to treat other severe forms of autoimmune and/ or inflammatory disease. Blockage of TNF-α has been effective in rheumatoid arthritis, psoriasis, Crohn’s disease, and ankylosing spondylitis. Other cytokine inhibitors are recombinant soluble TNF-α receptor (R) fused to human Ig and anakinra (soluble IL-1 receptor antagonist, or IL-1ra). The treatment of autoinflammatory syndromes (Table 342-6) with recombinant IL-1 receptor antagonist can prevent symptoms in these syndromes, because the overproduction of IL-1β is a hallmark of these diseases. TNF-αR-Fc fusion protein (etanercept) and IL-1ra act to inhibit the activity of pathogenic cytokines in rheumatoid arthritis, i.e., TNF-α and IL-1, respectively. Similarly, anti-IL-6, IFN-β, and IL-11 act to inhibit pathogenic proinflammatory cytokines. Anti-IL-6 (tocilizumab) inhibits IL-6 activity, whereas IFN-β and IL-11 decrease IL-1 and TNF-α production. Of particular note has been the successful use of IFN-γ in the treatment of the phagocytic cell defect in chronic granulomatous disease (Chap. 60). Th17 CD4 T cells have been implicated in the pathogenesis of pso riasis, ulcerative colitis, and other autoimmune diseases. Monoclonal antibodies have now been developed that target cytokines (IL-12, IL-23) that induce Th17 T cell differentiation, and are licensed by the FDA for treatment of psoriasis. Monoclonal antibodies that directly target IL-17 have also recently been licensed for psoriasis and psoriatic arthritis treatment. Monoclonal Antibodies to T and B Cells The OKT3 MAb against human T cells has been used for several years as a T cell– specific immunosuppressive agent that can substitute for horse anti thymocyte globulin (ATG) in the treatment of solid organ transplant rejection. OKT3 produces fewer allergic reactions than ATG but does induce human anti-mouse Ig antibody—thus limiting its use. Anti-CD4 MAb therapy has been used in trials to treat patients with rheumatoid arthritis. While inducing profound immunosuppression, anti-CD4 MAb treatment also induces susceptibility to severe infections. Treat ment of patients with a MAb against the T cell molecule CD40 ligand (CD154) is under investigation to induce tolerance to organ transplants, with promising results reported in animal studies. Monoclonal anti bodies to the CD25 (IL-2a) receptor (basiliximab) are being used for treatment of graft-versus-host disease in bone marrow transplantation, and anti-CD20 MAb (rituximab) is used to treat hematologic neo plasms, autoimmune diseases, kidney transplant rejection, and rheu matoid arthritis. The anti-IgE monoclonal antibody (omalizumab) is used for blocking antigen-specific IgE that causes hay fever and allergic rhinitis (Chap. 345); however, side effects of anti-IgE include increased risk of anaphylaxis. Studies have shown that TH 17 cells, in addition to TH 1, are mediators of inflammation in Crohn’s disease, and anti–IL-12/ CHAPTER 342 Introduction to the Immune System IL-23p40 antibody therapy has been studied as a treatment. It is important to realize the potential risks of these immunosuppres sive monoclonal antibodies. Natalizumab is a humanized IgG antibody against an a4 integrin that inhibits leukocyte migration into tissues and has been approved for treatment of multiple sclerosis in the United States. Both it and anti-CD20 (rituximab) have been associated with the onset of progressive multifocal leukoencephalopathy (PML)—a serious and usually fatal CNS infection caused by JC polyomavirus. Efali zumab, a humanized IgG monoclonal antibody previously approved for treatment of plaque psoriasis, has now been taken off the market due to reactivation of JC virus leading to fatal PML. Thus, use of any currently approved immunosuppressant immunotherapies should be undertaken with caution and with careful monitoring of patients according to FDA guidelines. Intravenous Immunoglobulin (IVIg) IVIg has been used successfully to block reticuloendothelial cell function and immune complex clearance in various immune cytopenias such as immune thrombocytopenia (Chap. 111). In addition, IVIg is useful for pre vention of tissue damage in certain inflammatory syndromes such as Kawasaki disease (Chap. 356) and as Ig replacement therapy for certain types of immunoglobulin deficiencies (Chap. 344). In addition, controlled clinical trials support the use of IVIg in selected patients with graft-versus-host disease, multiple sclerosis, myasthenia gravis, Guillain-Barré syndrome, and chronic demyelinating polyneuropathy. Stem Cell Transplantation Hematopoietic stem cell transplan tation (SCT) is now being comprehensively studied to treat several autoimmune diseases including systemic lupus erythematosus, multiple sclerosis, and scleroderma. The goal of immune reconstitution in auto immune disease syndromes is to replace a dysfunctional immune system with a normally reactive immune cell repertoire. Preliminary results in patients with scleroderma and lupus have showed encouraging results. Controlled clinical trials in these three diseases are now being launched in the United States and Europe to compare the toxicity and efficacy of conventional immunosuppression therapy with that of myeloablative autologous SCT. Recently, SCT was used in the setting of HIV-1 infection. HIV-1 infection of CD4+ T cells requires the presence of surface CD4 receptor and the chemokine receptor 5 (CCR5) co-receptor. Studies have demonstrated that patients who are homozygous for a 32-bp deletion in the CCR5 allele do not express CD4+ T cell CCR5 and thus are resistant to HIV-1 infection with HIV-1 strains that use this co-receptor. Stem cells from a homozygous CCR5 delta32 donor were transplanted to an HIV-infected patient following standard conditioning for such 2480 transplants, and the patient has maintained long-term control of the virus without antiretrovirals. Thus, a number of recent insights into immune system function have spawned a new field of interventional immunotherapy and have enhanced the prospect for development of more specific and nontoxic therapies for immune and inflammatory diseases. PART 11 Immune-Mediated, Inflammatory, and Rheumatologic Disorders ■FURTHER READING Crotty S: T follicular helper cell differentiation, function, and roles in disease. Immunity 41:529, 2014. Dupag* M, Bluston JA: Harnessing the plasticity of CD4+T cells to treat immune-mediated disease. Nat Rev Immunol 3:149, 2016. Kim BS et al: Targeting IL-17 in autoimmunity and inflammation. Arch Pharm Res 39:1537, 2016. Lvin B et al: Autophagy in immunity and inflammation. Nature 469:323, 2011. Mulay SR, Andrs HJ: Crystallopathies. N Engl J Med 374:25, 2016. Pdrsn HK et al: Human gut microbes impact host serum metabo lome and insulin sensitivity. Nature 535:376, 2016. Pfiffr JK, Virgin HW: Transkingdom control of viral infection and immunity in the mammalian intestine. Science 351:239, 2016. Ratn*r D et al: Bacterial secretion systems and regulation of inflam masome activation. J Leuk Bio 101(1):165, 2017. Yang F et al: The diverse biological functions of neutrophils, b
Alur Sesi: 01 Pretest → 02 MATERI (AKTIF) → 03 POSTTEST
Broty: "Materi selesai dibaca. Lanjutkan ke posttest untuk mengevaluasi pemahamanmu pada sesi ini."
- Langkah Selanjutnya: Lanjut ke Posttest Sesi 1 →
- Navigasi Blok: Daftar Sesi Hematoimmuno · Beranda